

COVID-19 vaccine BNT162b1 elicits human antibody and

Nature

586, 594-599

DOI: [10.1038/s41586-020-2814-7](https://doi.org/10.1038/s41586-020-2814-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
2	A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 218.	7.1	41
3	The known unknowns of T cell immunity to COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	122
4	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
5	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. <i>Immunity</i> , 2020, 53, 1281-1295.e5.	6.6	285
6	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
7	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
8	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
9	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
10	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
11	Nucleic Acid-Based Technologies Targeting Coronaviruses. <i>Trends in Biochemical Sciences</i> , 2021, 46, 351-365.	3.7	35
12	Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets. <i>Cell Systems</i> , 2021, 12, 102-107.e4.	2.9	35
13	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
14	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111008.	2.5	40
15	Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV. <i>Journal of Controlled Release</i> , 2021, 330, 1016-1033.	4.8	15
16	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
17	Individual and community-level risk for COVID-19 mortality in the United States. <i>Nature Medicine</i> , 2021, 27, 264-269.	15.2	70
18	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265

#	ARTICLE	IF	CITATIONS
19	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
20	Non-viral COVID-19 vaccine delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 137-151.	6.6	152
21	Is there a role for childhood vaccination against COVID-19?. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 9-16.	1.1	38
22	Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination. <i>Journal of Korean Medical Science</i> , 2021, 36, e158.	1.1	11
23	Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
24	Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines. <i>Clinical Infectious Diseases</i> , 2021, 73, 1320-1321.	2.9	10
25	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	9
26	Engineering SARS-CoV-2 using a reverse genetic system. <i>Nature Protocols</i> , 2021, 16, 1761-1784.	5.5	137
27	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. <i>Emerging Microbes and Infections</i> , 2021, 10, 342-355.	3.0	37
28	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	20
29	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers; Changing Epidemiology as the Pandemic Progresses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
30	COVID-19: Characteristics and Therapeutics. <i>Cells</i> , 2021, 10, 206.	1.8	177
31	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110467.	0.9	0
32	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
33	TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. <i>Pharmaceutics</i> , 2021, 13, 142.	2.0	129
35	The Worldwide Effort to Develop Vaccines for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 215-223.	0.8	3
36	Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. <i>Journal of Korean Medical Science</i> , 2021, 36, e229.	1.1	22
37	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1

#	ARTICLE	IF	CITATIONS
38	The evolutionary dynamics of endemic human coronaviruses. <i>Virus Evolution</i> , 2021, 7, veab020.	2.2	40
39	Declined Antibody Responses to COVID-19 mRNA Vaccine within First Three Months. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
40	Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development. <i>Radiation Research</i> , 2021, 195, 221-229.	0.7	10
41	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. <i>PLoS Pathogens</i> , 2021, 17, e1009161.	2.1	62
42	Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110292.	1.0	42
43	Vaccine responses in ageing and chronic viral infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3
44	Management of COVID-19 Infection During Pregnancy, Labor, and Puerperium. , 2021, , 63-89.		1
45	Vaccinology in the post-COVID-19 era. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
46	Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in Greece. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
47	mRNA vaccines for COVID-19: what, why and how. <i>International Journal of Biological Sciences</i> , 2021, 17, 1446-1460.	2.6	185
48	T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. <i>Clinical and Translational Immunology</i> , 2021, 10, e1341.	1.7	14
49	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. <i>Genome Medicine</i> , 2021, 13, 7.	3.6	193
50	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
51	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. <i>Vaccines</i> , 2021, 9, 61.	2.1	105
52	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. <i>ACS Nano</i> , 2021, 15, 9627-9637.	7.3	66
53	The Vaccine Supply Chain: A Call for Resilience Analytics to Support COVID-19 Vaccine Production and Distribution. <i>Risk, Systems and Decisions</i> , 2021, , 389-437.	0.5	21
57	The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. <i>Drugs in Context</i> , 2021, 10, 1-10.	1.0	77
60	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20

#	ARTICLE	IF	CITATIONS
61	Impact of Liposomal Drug Formulations on the RBCs Shape, Transmembrane Potential, and Mechanical Properties. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1710.	1.8	0
62	Unanticipated efficacy of SARS-CoV-2 vaccination in older adults. <i>Immunity and Ageing</i> , 2021, 18, 7.	1.8	20
63	mRNA vaccine for cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 41.	7.9	445
64	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
65	Nanotechnology-Based Antimicrobial and Antiviral Surface Coating Strategies. <i>Prosthesis</i> , 2021, 3, 25-52.	1.1	78
66	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. <i>Cell</i> , 2021, 184, 881-898.	13.5	56
67	Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. <i>Pharmaceutics</i> , 2021, 13, 278.	2.0	17
68	Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap <sup>®</sup> Analog by In Vitro Transcription. <i>Current Protocols</i> , 2021, 1, e39.	1.3	103
70	COVID-19 mRNA vaccines. <i>Journal of Genetics and Genomics</i> , 2021, 48, 107-114.	1.7	59
71	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. <i>Vaccines</i> , 2021, 9, 147.	2.1	175
72	The challenge of avidity determination in SARS-CoV-2 serology. <i>Journal of Medical Virology</i> , 2021, 93, 3092-3104.	2.5	32
73	mRNA vaccine: a potential therapeutic strategy. <i>Molecular Cancer</i> , 2021, 20, 33.	7.9	188
74	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
76	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
80	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
83	A short discussion about the SARS-CoV-2 mRNA-1273 vaccine. <i>International Journal of Infectious Diseases</i> , 2021, 104, 532-533.	1.5	3
84	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158.	3.7	49
85	A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48

#	ARTICLE	IF	CITATIONS
86	COVID-19 vaccines: modes of immune activation and future challenges. <i>Nature Reviews Immunology</i> , 2021, 21, 195-197.	10.6	529
87	SARS-CoV-2 vaccines in patients with SLE. <i>Lupus Science and Medicine</i> , 2021, 8, e000479.	1.1	30
88	mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety. <i>Journal of Occupational and Environmental Medicine</i> , 2021, 63, e314-e317.	0.9	3
90	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
91	Acute Immune Thrombocytopenia following administration of Shingrix recombinant zoster vaccine. <i>American Journal of Hematology</i> , 2021, 96, E136-E137.	2.0	8
93	Self-assembled mRNA vaccines. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 83-112.	6.6	248
94	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
95	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	1.3	27
96	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG, lateral flow assay. <i>PLoS ONE</i> , 2021, 16, e0247797.	1.1	20
97	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. <i>Frontiers in Immunology</i> , 2021, 12, 657711.	2.2	50
98	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 <sup>+</sup> T cell responses. <i>Science Immunology</i> , 2021, 6, .	5.6	143
99	Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination. , 2021, 46, E210-E211.		22
100	Medicinal Plants in COVID-19: Potential and Limitations. <i>Frontiers in Pharmacology</i> , 2021, 12, 611408.	1.6	56
101	High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. <i>Future Drug Discovery</i> , 2021, 3, .	0.8	10
102	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
103	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , 2021, 9, 227.	2.1	47
104	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. <i>Viruses</i> , 2021, 13, 418.	1.5	51
106	Detection of anti-SARS-CoV-2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA). <i>Analytical Science Advances</i> , 2021, 2, 440.	1.2	4

#	ARTICLE	IF	CITATIONS
109	The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 163-165.	0.2	6
110	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity, 2021, 54, 542-556.e9.	6.6	72
111	Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments. Cells, 2021, 10, 591.	1.8	16
117	Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology, 2021, 67, 189-212.	0.8	11
120	Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective caseâ€“control study in an Arab Gulf country. Aging Clinical and Experimental Research, 2021, 33, 1415-1422.	1.4	54
121	Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer, 2021, 20, 52.	7.9	90
122	Therapeutic RNA Delivery for COVID and Other Diseases. Advanced Healthcare Materials, 2021, 10, e2002022.	3.9	31
125	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	6.6	262
127	Nanotechnology, equity and global health. Nature Nanotechnology, 2021, 16, 358-361.	15.6	24
130	Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. Current Opinion in Infectious Diseases, 2021, 34, 181-186.	1.3	34
131	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. International Journal of Molecular Sciences, 2021, 22, 3059.	1.8	36
132	Lichen planus arising after COVIDâ€™19 vaccination. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e414-e415.	1.3	65
133	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2021, 170, 113-141.	6.6	71
135	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
136	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	4.7	100
139	COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurology: Clinical Practice, 2021, 11, 358-361.	0.8	14
140	Cervical Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2021, 27, 4953-4973.	3.2	129
142	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	5.1	87

#	ARTICLE	IF	CITATIONS
143	Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 359.	2.1	222
144	Emerging concepts in the science of vaccine adjuvants. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 454-475.	21.5	601
145	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceuticals</i> , 2021, 14, 406.	1.7	101
146	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	5
147	A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions. <i>Drug Research</i> , 2021, 71, 348-350.	0.7	0
148	Premarket Development Times for Innovative Vaccines—To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	1
149	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. <i>Vaccines</i> , 2021, 9, 433.	2.1	85
151	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
154	COVID-19 immunity and vaccines: what a pharmacist needs to know. <i>Asian Biomedicine</i> , 2021, 15, 51-67.	0.2	0
157	Immunology of biodegradable nanoparticles: a brief overview on a wide growing field. , 0, , 48-60.		5
159	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. <i>Journal of Pharmacy Practice</i> , 2022, 35, 947-951.	0.5	82
162	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009064.	2.1	21
163	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. <i>Nature Medicine</i> , 2021, 27, 1062-1070.	15.2	114
164	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. <i>Science</i> , 2021, 372, 1418-1423.	6.0	286
165	Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 648472.	1.8	20
166	Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. <i>Transfusion</i> , 2021, 61, 2099-2106.	0.8	27
167	The avalanche of antirheumatic therapy and COVID-19 vaccinations. <i>Rheumatology</i> , 2021, 60, 3490-3491.	0.9	2
168	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 289-331.	6.6	84



#	ARTICLE	IF	CITATIONS
169	Antibodies and Vaccines Target RBD of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671633.	1.6	108
170	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	154
171	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology</i> , The, 2021, 22, 765-778.	5.1	491
172	Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. <i>Science Immunology</i> , 2021, 6, .	5.6	556
173	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <i>Npj Vaccines</i> , 2021, 6, 65.	2.9	36
174	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32
175	Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread. <i>PLoS Pathogens</i> , 2021, 17, e1009509.	2.1	36
176	Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults. <i>Immunological Investigations</i> , 2021, 50, 810-820.	1.0	10
178	Single-cell multi-omics analysis of the immune response in COVID-19. <i>Nature Medicine</i> , 2021, 27, 904-916.	15.2	452
179	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
180	Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. <i>Nature Medicine</i> , 2021, 27, 981-984.	15.2	504
182	Review of the COVID-19 Risk in Multiple Sclerosis. , 2021, 3, 68-77.		24
184	Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes. <i>Public Health</i> , 2021, 193, 57-60.	1.4	10
185	The EFIS vaccination task force expert report. <i>European Journal of Immunology</i> , 2021, 51, 1023-1027.	1.6	1
188	Production of SARS-CoV-2 Virus-Like Particles in Insect Cells. <i>Vaccines</i> , 2021, 9, 554.	2.1	19
190	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Epidemiology and Vaccinology in Nigeria. <i>International Journal of Travel Medicine and Global Health</i> , 2021, 9, 60-69.	0.1	2
191	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
192	Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination. <i>Journal of Immunology</i> , 2021, 206, 2503-2507.	0.4	11

#	ARTICLE	IF	CITATIONS
193	Vaccination strategy and anti - SARS-CoV-2â€™S titers in healthcare workers of the INT â€™ IRCCS â€™Fondazione Pascaleâ€™Cancer Center (Naples, Italy). <i>Infectious Agents and Cancer</i> , 2021, 16, 32.	1.2	15
195	Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVIDâ€™19 mRNA vaccine. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3465.	1.7	203
196	The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 106, 61-64.	1.5	65
197	Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 423-424.	0.5	5
200	Chemoâ€™Enzymatic Modification of the 5â€™2 Cap Maintains Translation and Increases Immunogenic Properties of mRNA. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 13280-13286.	7.2	34
201	Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients. <i>Transplantation</i> , 2021, 105, e99-e99.	0.5	6
203	Comparative Analysis of Antigen-Specific Antiâ€™SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. <i>Journal of Immunology</i> , 2021, 206, 2393-2401.	0.4	19
204	Coronavirus disease 2019 (COVIDâ€™19) vaccines: A concise review. <i>Oral Diseases</i> , 2022, 28, 2326-2336.	1.5	36
205	Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. <i>Vaccine</i> , 2021, 39, 2995-3006.	1.7	71
206	SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 118-120.	0.1	3
208	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2022, 74, 707-710.	2.9	10
210	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3540-3549.	3.3	33
211	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	15.2	365
212	American College of Rheumatology Guidance for COVIDâ€™19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021, 73, 1093-1107.	2.9	146
213	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
214	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
216	Contributions of immigrants to biomedical research in the US: a personal reflection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	0
217	The current landscape of nucleic acid therapeutics. <i>Nature Nanotechnology</i> , 2021, 16, 630-643.	15.6	578

#	ARTICLE	IF	CITATIONS
218	Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety. <i>Biomedicines</i> , 2021, 9, 530.	1.4	54
219	Eine chemoenzymatische Modifizierung der 5'â€Kappe erhalt die Translation und erhahrt die Immunogenitat der mRNA. <i>Angewandte Chemie</i> , 2021, 133, 13390-13397.	1.6	2
220	Trinucleotide Cap Analogue Bearing a Locked Nucleic Acid Moiety: Synthesis, mRNA Modification, and Translation for Therapeutic Applications. <i>Organic Letters</i> , 2021, 23, 4133-4136.	2.4	19
221	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , 2021, 35, 3573-3577.	3.3	41
223	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1-2.	1.0	3
224	Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus. <i>Carbohydrate Polymers</i> , 2021, 260, 117797.	5.1	21
225	Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1709-1716.	0.4	123
226	Vaccines for immunoprevention of cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	39
227	Coincidental SARS-CoV-2 infection and mRNA vaccination: a case report addressing the most important clinical questions. <i>Infection</i> , 2021, 49, 785-788.	2.3	0
230	Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	16
232	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
233	Pernio after COVID-19 vaccination. <i>British Journal of Dermatology</i> , 2021, 185, 445-447.	1.4	26
238	The need for ethical and pragmatic strategies for sample and data collection during public health emergenciesâ€minimizing missed opportunities. <i>European Heart Journal</i> , 2021, 42, 3114-3116.	1.0	0
239	The safety of Covid-19 mRNA vaccines: a review. <i>Patient Safety in Surgery</i> , 2021, 15, 20.	1.1	150
240	Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants. <i>Vaccines</i> , 2021, 9, 517.	2.1	17
241	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	2.1	228
242	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1312-1316.	0.5	154
244	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583

#	ARTICLE	IF	CITATIONS
245	Safety and Considerations of the COVID-19 Vaccine Massive Deployment. <i>Virologica Sinica</i> , 2021, 36, 1097-1103.	1.2	3
247	COVID-19 vaccination for patients with primary immunodeficiency. <i>LymphoSign Journal</i> , 2021, 8, 37-45.	0.1	8
248	Future considerations for the mRNA-lipid nanoparticle vaccine platform. <i>Current Opinion in Virology</i> , 2021, 48, 65-72.	2.6	63
253	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 577-588.	0.7	2
254	B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1672-1677.	2.8	26
255	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. <i>Npj Vaccines</i> , 2021, 6, 84.	2.9	52
257	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e30-e45.	2.9	61
258	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. <i>ACS Central Science</i> , 2021, 7, 1191-1204.	5.3	34
259	Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. <i>Vaccines</i> , 2021, 9, 587.	2.1	6
260	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. <i>Advances in Molecular Pathology</i> , 2021, , .	0.2	1
261	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	5.6	223
263	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
264	Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 70-88.	6.6	6
265	First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	116
266	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 999-1006.	1.2	55
267	Contemporary RNA Therapeutics for Glioblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 8-12.	1.8	10
268	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. <i>Frontiers in Immunology</i> , 2021, 12, 710263.	2.2	32
269	Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 1699-1700.	0.4	37

#	ARTICLE	IF	CITATIONS
270	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
271	Predictive Markers of Immunogenicity and Efficacy for Human Vaccines. <i>Vaccines</i> , 2021, 9, 579.	2.1	25
272	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. <i>Nature Communications</i> , 2021, 12, 3587.	5.8	71
273	The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination. <i>Journal of Human Lactation</i> , 2021, 37, 477-484.	0.8	40
274	How has nanomedical innovation contributed to the COVID-19 vaccine development?. <i>Nanomedicine</i> , 2021, 16, 1179-1181.	1.7	11
275	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 705-715.	8.2	26
276	Advances in Neutralization Assays for SARS-CoV-2. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13088.	1.3	40
277	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021, 596, 109-113.	13.7	586
278	Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. <i>Drugs in R and D</i> , 2021, 21, 341-350.	1.1	10
279	Phenotypes and Functions of SARS-CoV-2-Reactive T Cells. <i>Molecules and Cells</i> , 2021, 44, 401-407.	1.0	16
280	Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID). <i>International Journal of Molecular Sciences</i> , 2021, 22, 6937.	1.8	20
281	Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0038821.	1.8	99
282	Guidelines for Mountain Rescue During the COVID-19 Pandemic: Official Guidelines of the International Commission for Alpine Rescue. <i>High Altitude Medicine and Biology</i> , 2021, 22, 128-141.	0.5	5
284	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. <i>MBio</i> , 2021, 12, e0069621.	1.8	61
287	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. <i>Comptes Rendus - Biologies</i> , 2021, 344, 77-110.	0.1	4
288	Maternal nutrients and effects of gestational COVID-19 infection on fetal brain development. <i>Clinical Nutrition ESPEN</i> , 2021, 43, 1-8.	0.5	16
289	Infection kinetics of Covid-19 and containment strategy. <i>Scientific Reports</i> , 2021, 11, 11606.	1.6	6
290	SARS-CoV-2 vaccines: Lights and shadows. <i>European Journal of Internal Medicine</i> , 2021, 88, 1-8.	1.0	90

#	ARTICLE	IF	CITATIONS
291	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. <i>Cell Host and Microbe</i> , 2021, 29, 917-929.e4.	5.1	132
292	COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	33
293	Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases. <i>European Journal of Dermatology</i> , 2021, 31, 415-417.	0.3	4
294	Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results. <i>Vaccines</i> , 2021, 9, 675.	2.1	40
295	Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers. <i>Journal of Virus Eradication</i> , 2021, 7, 100046.	0.3	13
297	A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Vaccines</i> , 2021, 9, 641.	2.1	5
298	Minimal change disease following vaccination for SARS-CoV-2. <i>Journal of Nephrology</i> , 2021, 34, 1039-1040.	0.9	26
300	Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. <i>Lancet HIV</i> , the, 2021, 8, e317-e318.	2.1	36
301	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
302	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
303	Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection. <i>Revue Neurologique</i> , 2021, 177, 1237-1240.	0.6	32
305	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
306	Eritema palpebral tras vacunaci3n frente a la infecci3n por coronavirus. <i>Medicina Clínica</i> , 2021, , .	0.3	0
307	Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e649-e651.	1.3	54
309	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
310	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. <i>Journal of Intensive Medicine</i> , 2021, 1, 4-13.	0.8	9
311	Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1565-1569.	0.4	39
312	The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. <i>Clinics in Dermatology</i> , 2021, 39, 966-984.	0.8	42



#	ARTICLE	IF	CITATIONS
313	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1654-1664.	4.6	200
314	SARS-CoV-2 serology testing: Progress and challenges. <i>Journal of Immunological Methods</i> , 2021, 494, 113060.	0.6	21
315	The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection. <i>Archives of Virology</i> , 2021, 166, 2649-2672.	0.9	21
316	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. <i>PLoS Pathogens</i> , 2021, 17, e1009761.	2.1	66
318	“COVID arm™” histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-CoV2 SARS-CoV2 vaccine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e730-e732.	1.3	15
319	Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. <i>Blood Advances</i> , 2021, 5, 2794-2798.	2.5	47
320	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
322	Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5211-5232.	3.3	24
323	It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies. <i>Haematologica</i> , 2022, 107, 572-573.	1.7	5
324	Potency of BNT162b2 and mRNA-CoV2 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
325	COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?. <i>Biomolecules</i> , 2021, 11, 1020. Zhejiang Da 524-528.	1.8	28
326	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228.	0.3	7
328	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
329	COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?. <i>Biomolecules</i> , 2021, 11, 1020.	1.8	28
330	The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 74, 1268-1270.	2.9	118
331	Systems vaccinology of the BNT162b2 mRNA vaccine in humans. <i>Nature</i> , 2021, 596, 410-416.	13.7	313
332	SARS-CoV-2 Antibodies Detected in Mothers' Milk Post-Vaccination. <i>Journal of Human Lactation</i> , 2021, 37, 492-498.	0.8	59
334	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6

#	ARTICLE	IF	CITATIONS
336	mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. <i>Pharmaceutics</i> , 2021, 13, 1040.	2.0	7
337	Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. <i>Vaccines</i> , 2021, 9, 820.	2.1	18
339	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 719077.	2.2	9
340	Facts and Figures on Materials Science and Nanotechnology Progress and Investment. <i>ACS Nano</i> , 2021, 15, 15940-15952.	7.3	48
344	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. <i>Nature</i> , 2021, 597, 268-273.	13.7	279
345	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. <i>Lancet, The</i> , 2021, 398, 207-209.	6.3	112
346	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 121-130.	6.3	316
347	<scp>BNT162b2 COVID</scp>â€19 vaccine is significantly less effective in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2021, 96, 1195-1203.	2.0	142
349	SARS-CoV-2 vaccination in the context of original antigenic sin. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-3.	1.4	5
350	Transplantation programs facing lack of empirical evidence on SARSâ€CoVâ€2 vaccination: A society recommendation consensus update. <i>Transplant Infectious Disease</i> , 2021, 23, e13696.	0.7	4
355	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
356	Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7919.	1.8	8
357	Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. <i>JAMA Oncology</i> , 2021, 7, 1507.	3.4	131
358	Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 625-634.	1.7	83
360	COVID-19 Vaccine mRNA BNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women. <i>Vaccines</i> , 2021, 9, 785.	2.1	22
362	Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, e15-e15.	0.5	40
363	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Antiâ€SARS-CoV-2 Antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	36
364	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434



#	ARTICLE	IF	CITATIONS
365	A Literature Review on the Vaccination of COVID-19 in Pregnant and Breastfeeding Women: Effectiveness and Safety. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 234-237.	0.1	1
366	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell and Bioscience, 2021, 11, 168.	2.1	69
367	In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. Turkish Journal of Biology, 2021, 45, 442-458.	2.1	3
368	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases, The, 2021, 21, 1107-1119.	4.6	345
369	Two cases of papulo-erythematous eruptions following COVID-19 vaccinations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e868-e870.	1.3	8
370	Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. Journal of the National Cancer Institute, 2022, 114, 203-209.	3.0	65
372	2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology. Nanomedicine, 2021, 16, 1635-1640.	1.7	12
374	Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncology, 2021, 7, 1133.	3.4	232
375	Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination. Sensors, 2021, 21, 5857.	2.1	32
376	Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients. Journal of Hepatology, 2021, 75, 265-266.	1.8	8
378	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infection, Genetics and Evolution, 2021, 92, 104869.	1.0	49
379	SARS-CoV-2 vaccines â€” the biggest medical research project of the 21st century. Current Opinion in Virology, 2021, 49, 52-57.	2.6	12
380	An Update on mRNA-Based Viral Vaccines. Vaccines, 2021, 9, 965.	2.1	14
381	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine, 2021, 70, 103524.	2.7	53
382	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
383	Active Covid-19 infection and transmission after the first dose of the BNT162b2 mRNA vaccination in Saudi Arabia: A case report. Journal of Infection and Public Health, 2021, 14, 1123-1125.	1.9	7
384	Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations. MBio, 2021, 12, e0118821.	1.8	30
385	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Immunologic Research, 2021, 69, 576-583.	1.3	34

#	ARTICLE	IF	CITATIONS
386	Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report. <i>Frontiers in Neurology</i> , 2021, 12, 721502.	1.1	37
387	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e60-e75.	2.9	126
388	Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, e226-e233.	0.5	46
389	Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. <i>Advanced Therapeutics</i> , 2021, 4, 2100104.	1.6	11
391	Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. <i>Future Oncology</i> , 2021, 17, 4071-4079.	1.1	36
392	Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. <i>Cancers</i> , 2021, 13, 4191.	1.7	34
393	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	1.5	9
394	Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. <i>Journal of Controlled Release</i> , 2021, 336, 354-374.	4.8	30
395	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
396	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	21.5	577
397	Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine. <i>American Journal of Clinical Pathology</i> , 2022, 157, 212-218.	0.4	6
398	COVID-19 post-vaccination recommendations for primary immunodeficiency. <i>LymphoSign Journal</i> , 0, 1-6.	0.1	2
399	Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 450-456.	0.9	109
400	Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e583-e592.	2.2	211
401	SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications. <i>ACS Sensors</i> , 2021, 6, 2815-2837.	4.0	24
402	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2021, 9, 848.	2.1	64
404	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	2.6	120
405	Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. <i>International Journal of Infectious Diseases</i> , 2021, 110, 229-231.	1.5	15

#	ARTICLE	IF	CITATIONS
406	Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapyâ€”A Single-Center Prospective Cohort Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 788-794.	0.6	125
409	Antibody response and self-reported adverse reactions following vaccination with Comirnaty: a pilot study from a Croatian university hospital. <i>Journal of Clinical Pathology</i> , 2022, 75, 782-786.	1.0	10
410	A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. <i>Journal of Virology</i> , 2021, 95, e0059221.	1.5	11
411	A surrogate cellâ€based SARSâ€CoVâ€ spike blocking assay. <i>European Journal of Immunology</i> , 2021, 51, 2665-2676.	1.6	3
412	Newâ€onset and exacerbations of psoriasis after mRNA COVIDâ€19 vaccines: two sides of the same coin?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	20
413	Ethylenediamine derivatives efficiently react with oxidized RNA 3â€ ends providing access to mono and dually labelled RNA probes for enzymatic assays and <i>in vivo</i> translation. <i>Nucleic Acids Research</i> , 2022, 50, e3-e3.	6.5	4
414	Adverse events and preventive measures related to COVID-19 vaccines. <i>Clinical and Experimental Emergency Medicine</i> , 2021, 8, 153-159.	0.5	1
415	Perioperative use of intra-articular steroids during the COVID-19 pandemic. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, , 1.	0.6	0
416	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
417	Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. <i>American Journal of Kidney Diseases</i> , 2021, 78, 469-470.	2.1	42
418	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. <i>Vaccines</i> , 2021, 9, 999.	2.1	23
419	To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis. <i>Frontiers in Immunology</i> , 2021, 12, 733418.	2.2	20
420	Virusâ€Mimic mRNA Vaccine for Cancer Treatment. <i>Advanced Therapeutics</i> , 2021, 4, 2100144.	1.6	11
421	Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4121-4125.	1.4	3
422	Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. <i>Clinical Infectious Diseases</i> , 2022, 75, e792-e804.	2.9	73
423	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. <i>Lancet Regional Health - Europe</i> , The, 2021, 10, 100208.	3.0	446
424	Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>JAMA Neurology</i> , 2021, 78, 1510.	4.5	134
425	Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan. <i>Journal of Clinical Medicine</i> , 2021, 10, 4341.	1.0	3

#	ARTICLE	IF	CITATIONS
426	Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. <i>Translational Psychiatry</i> , 2021, 11, 499.	2.4	35
427	Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 303.e1-303.e17.	0.7	471
428	Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. <i>Annals of Internal Medicine</i> , 2021, 174, 1336-1338.	2.0	122
429	BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, 999-1009.	5.2	279
430	Recurrence of Graves' Disease (a Th1-type Cytokine Disease) Following SARS-CoV-2 mRNA Vaccine Administration: A Simple Coincidence?. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002807.	0.2	23
431	Nucleic acid delivery and nanoparticle design for COVID vaccines. <i>MRS Bulletin</i> , 2021, 46, 832-839.	1.7	12
432	Immune Responses against SARS-CoV-2—Questions and Experiences. <i>Biomedicines</i> , 2021, 9, 1342.	1.4	10
433	Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19. <i>Sustainable Cities and Society</i> , 2021, 72, 103046.	5.1	25
434	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
436	Saliva-Based ELISAs for Effective SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 701411.	2.2	5
437	Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis. <i>Journal of Neuroimmunology</i> , 2021, 358, 577632.	1.1	13
438	Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1273 mRNA vaccine by commercial antibody tests. <i>Vaccine</i> , 2021, 39, 5563-5570.	1.7	14
439	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
440	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
441	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
442	Impact of methotrexate on first-dose COVID-19 mRNA vaccination. <i>Lancet Rheumatology</i> , 2021, 3, e607-e609.	2.2	6
443	Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. <i>Clinical Microbiology and Infection</i> , 2022, 28, 139.e1-139.e4.	2.8	29
444	SARS-CoV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	1.7	23

#	ARTICLE	IF	CITATIONS
445	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
448	Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches. <i>MSystems</i> , 2021, 6, e0038821.	1.7	10
450	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113889.	6.6	48
451	A case of anti-GBM nephritis following centipede bites and COVID-19 vaccination. <i>CEN Case Reports</i> , 2022, 11, 166-170.	0.5	11
452	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
453	Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. <i>Immunity</i> , 2021, 54, 2133-2142.e3.	6.6	367
454	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. <i>International Journal of Infectious Diseases</i> , 2021, 113, 1-6.	1.5	11
455	Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. <i>Molecular Therapy</i> , 2021, 29, 2769-2781.	3.7	20
456	Chlorine dioxide is a more potent antiviral agent against SARS-CoV-2 than sodium hypochlorite. <i>Journal of Hospital Infection</i> , 2021, 118, 20-26.	1.4	33
457	Is Meteorology a Factor to COVID-19 Spread in a Tropical Climate?. <i>Earth Systems and Environment</i> , 2021, 5, 1-10.	3.0	1
458	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e52-e58.	4.6	59
459	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	89
461	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. <i>Vaccines</i> , 2021, 9, 1028.	2.1	11
462	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
463	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
464	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
465	Nucleic acid delivery for therapeutic applications. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113834.	6.6	122
466	Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 1033.	2.1	146

#	ARTICLE	IF	CITATIONS
467	Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®). <i>Vaccines</i> , 2021, 9, 1063.	2.1	27
468	Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. <i>Frontiers in Public Health</i> , 2021, 9, 732787.	1.3	27
469	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. <i>Microbiology Spectrum</i> , 2021, 9, e0034121.	1.2	114
470	Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVER Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. <i>Cancers</i> , 2021, 13, 4621.	1.7	29
472	Delivering the message: How a novel technology enabled the rapid development of effective vaccines. <i>Cell</i> , 2021, 184, 5271-5274.	13.5	5
473	Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 113-121.	0.6	113
474	COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?. <i>Kidney International</i> , 2021, 100, 959-965.	2.6	65
476	An immunologist's perspective on anti-COVID-19 vaccines. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, Publish Ahead of Print, 545-552.	1.1	4
477	The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. <i>Kidney International</i> , 2021, 100, 928-936.	2.6	61
478	Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 880.e1-880.e4.	0.6	27
479	Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. <i>BMC Medicine</i> , 2021, 19, 255.	2.3	137
480	Impact of COVID-19 on Pediatric Immunocompromised Patients. <i>Pediatric Clinics of North America</i> , 2021, 68, 1029-1054.	0.9	16
481	Immune response to COVID-19 in older adults. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1082-1089.	0.3	13
482	Biomaterials, biological molecules, and polymers in developing vaccines. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 813-828.	4.0	14
483	Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2021, 78, 571-581.	2.1	100
484	Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1126-1130.	1.4	7
485	Herpes zoster after COVID vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 111, 169-171.	1.5	48
486	COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. <i>Lancet Rheumatology</i> , The, 2021, 3, e724-e736.	2.2	76



#	ARTICLE	IF	CITATIONS
487	Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 501-503.	0.5	19
488	COVID-19 in Children. <i>Pediatric Clinics of North America</i> , 2021, 68, 961-976.	0.9	21
489	Administration of COVID-19 vaccines in immunocompromised patients. <i>International Immunopharmacology</i> , 2021, 99, 108021.	1.7	51
490	Serological response to a single dose of a SARS-CoV-2 mRNA vaccine. <i>Journal of Virological Methods</i> , 2021, 296, 114223.	1.0	5
491	Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103203.	0.9	2
492	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. <i>EBioMedicine</i> , 2021, 72, 103589.	2.7	16
493	The mystery behind the nostrils – technical clues for successful nasal epithelial cell cultivation. <i>Annals of Anatomy</i> , 2021, 238, 151748.	1.0	1
494	Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort. <i>Science Bulletin</i> , 2021, 66, 2312-2319.	4.3	26
495	The impact of MDSCs on the efficacy of preventive and therapeutic HIV vaccines. <i>Cellular Immunology</i> , 2021, 369, 104440.	1.4	6
496	PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity. <i>Journal of Controlled Release</i> , 2021, 339, 156-163.	4.8	12
497	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
498	Case report of lymph node activation mimicking cancer progression: A false positive F18 FDG PET CT after COVID-19 vaccination. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100092.	0.1	6
499	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112260.	2.5	7
501	Immune Response After One Dose of Intramuscular Vaccination With the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Healthcare Workers: The Effect of Age and Vitamin D. <i>SSRN Electronic Journal</i> , 0, .	0.4	0
502	COVID-19 pandemic and the answer of science: a year in review. <i>Anais Da Academia Brasileira De Ciencias</i> , 2021, 93, e20210543.	0.3	4
503	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
505	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	14
506	SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. <i>Immune Network</i> , 2021, 21, e2.	1.6	12

#	ARTICLE	IF	CITATIONS
507	Cellular Immune Responses are Preserved and May Contribute to&nbsp;Chadox1 ChAdOx1 nCoV-19&nbsp;Vaccine Effectiveness Against Infection Due to SARS-CoV-2 BÂ·1Â·617Â·2 Delta Variant Despite Reduced Virus Neutralisation. SSRN Electronic Journal, 0, , .	0.4	8
508	Current State of the First COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 30.	2.1	64
509	T cell response to SARS-CoV-2 infection in humans: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0245532.	1.1	228
510	COVID-19 vaccination in immunocompromised patients. <i>Clinical Rheumatology</i> , 2021, 40, 797-798.	1.0	49
511	IgG antibody titers to SARS-CoV-2 reveal a distinct efficacy of multiple sclerosis-modifying therapies to curtail lymphocyte compartments. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110221.	1.5	0
512	The Case Against Delaying Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine Boosting Doses. <i>Clinical Infectious Diseases</i> , 2021, 73, 1321-1323.	2.9	22
513	Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. <i>Vaccines</i> , 2021, 9, 76.	2.1	28
514	SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. <i>Epidemiology and Infection</i> , 2021, 149, e153.	1.0	0
516	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
517	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
518	Nanomaterial Delivery Systems for mRNA Vaccines. <i>Vaccines</i> , 2021, 9, 65.	2.1	310
519	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	59
520	Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110128.	1.5	259
521	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <i>Science China Life Sciences</i> , 2020, 63, 1833-1849.	2.3	29
522	Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States. <i>ACS Central Science</i> , 2021, 7, 274-291.	5.3	46
523	All eyes on a hurdle race for a SARS-CoV-2 vaccine. <i>Nature</i> , 2020, 586, 501-502.	13.7	23
537	SARS-CoV-2 Spike Protein and Lung Vascular Cells. <i>Journal of Respiration</i> , 2021, 1, 40-48.	0.4	6
538	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. <i>Vaccines</i> , 2020, 8, 783.	2.1	13



#	ARTICLE	IF	CITATIONS
539	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. <i>Vaccines</i> , 2021, 9, 3.	2.1	74
540	Neutralizing SARS-CoV-2. <i>ELife</i> , 2020, 9, .	2.8	5
541	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
542	Status of Humoral and Cellular Immune Responses within 12 Months Following CoronaVac Vaccination Against COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
543	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 1849-1860.	1.9	16
544	Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. <i>BMC Clinical Pathology</i> , 2021, 14, 2632010X2110492.	0.7	9
545	Emerging Lipid-Coated Silica Nanoparticles for Cancer Therapy. <i>Nanotechnology in the Life Sciences</i> , 2021, , 335-361.	0.4	4
546	Detección de anticuerpos neutralizantes en profesionales de la salud vacunados contra el SARS-CoV-2. <i>Horizonte Médico</i> , 2021, 21, e1539.	0.1	1
547	Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. <i>Viruses</i> , 2021, 13, 1972.	1.5	22
549	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.5	61
550	mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells Persist at 6 Months and Recognize the Delta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e898-e901.	2.9	25
551	BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease. <i>Vaccines</i> , 2021, 9, 1164.	2.1	8
552	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. <i>IScience</i> , 2021, 24, 103341.	1.9	47
553	T cell immunity to SARS-CoV-2. <i>Seminars in Immunology</i> , 2021, 55, 101505.	2.7	55
555	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	4
556	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	13.7	194
557	SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. <i>PLoS Biology</i> , 2021, 19, e3001425.	2.6	71
558	<scp>COVID</scp>â€™19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	2.8	119

#	ARTICLE	IF	CITATIONS
559	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
560	Allotypic variation in antigen processing controls antigenic peptide generation from SARS-CoV-2 S1 spike glycoprotein. <i>Journal of Biological Chemistry</i> , 2021, 297, 101329.	1.6	5
561	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
562	Reply. <i>Liver Transplantation</i> , 2022, 28, 515-516.	1.3	0
563	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <i>FASEB Journal</i> , 2021, 35, e21970.	0.2	22
564	Similarities and Differences between Na <sup>+</sup> and K <sup>+</sup> Distributions around DNA Obtained with Three Popular Water Models. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 7246-7259.	2.3	16
565	Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. <i>European Journal of Cancer</i> , 2021, 159, 259-274.	1.3	50
566	Single BNT162b2 vaccine dose produces seroconversion in under 60Ås cohort. <i>Vaccine</i> , 2021, 39, 6902-6906.	1.7	6
567	Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses. <i>Frontiers in Immunology</i> , 2021, 12, 752397.	2.2	14
568	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
569	Vaccines against COVID-19: Priority to mRNA-Based Formulations. <i>Cells</i> , 2021, 10, 2716.	1.8	17
570	Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115573.	0.8	25
571	Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2022, 35, 167-170.	0.3	23
575	Gene Therapy â€œMade in Germanyâ€: A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy. <i>Human Gene Therapy</i> , 2021, 32, 987-996.	1.4	3
576	Acute Corneal Transplant Rejection After COVID-19 Vaccination. <i>Cornea</i> , 2022, 41, 121-124.	0.9	26
577	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
579	Development of synthetic antigen vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3855-3870.	1.4	4
580	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). <i>BMJ Open</i> , 2021, 11, e055611.	0.8	22

#	ARTICLE	IF	CITATIONS
581	Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658932.	1.6	5
582	BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 41, 101158.	3.2	64
583	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112282.	2.5	10
584	Humoral immune response in multiple sclerosis patients following Pfizer BNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. <i>Journal of Neuroimmunology</i> , 2021, 361, 577746.	1.1	63
586	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
587	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
588	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	2.5	8
589	BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 38-44.	2.4	12
590	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
592	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2021, 6, 100266.	0.2	6
593	Immunology and controlling of coronaviruses; the current enemy for humanity: A review. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	3
594	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
595	Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. <i>Blood</i> , 2022, 139, 142-147.	0.6	63
596	Decisive conditions for strategic vaccination against SARS-CoV-2. <i>Chaos</i> , 2021, 31, 101105.	1.0	4
597	New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. <i>Vaccines</i> , 2021, 9, 1252.	2.1	32
598	Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination. <i>Cornea</i> , 2022, 41, 252-253.	0.9	13
599	Smart Delivery of Monoclonal Antibodies from a Magnetic Responsive Microgel Nanocomposite. <i>ACS Applied Bio Materials</i> , 2021, 4, 8487-8497.	2.3	7
600	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. <i>Immunity</i> , 2021, 54, 2877-2892.e7.	6.6	260

#	ARTICLE	IF	CITATIONS
601	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS Central Science, 2021, 7, 1863-1873.	5.3	20
602	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Scientific Reports, 2021, 11, 21849.	1.6	26
604	Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. JAMA - Journal of the American Medical Association, 2021, 326, 2203.	3.8	104
605	Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. Journal of Clinical Virology, 2021, 145, 105024.	1.6	33
606	Steroid-responsive aseptic meningitis after BNT162b2 SARS-CoV-2 vaccine. Revue Neurologique, 2022, 178, 160-161.	0.6	10
607	BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eabl5344.	5.6	166
608	Appendicitis as a possible safety signal for the COVID-19 vaccines. Vaccine: X, 2021, 9, 100122.	0.9	14
609	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clinical and Experimental Medicine, 2022, 22, 477-485.	1.9	18
612	Trend topics in prestigious and popular medical journals: The effect of Covid-19.. Acta Medica Alanya, 2020, 4, 207-208.	0.2	3
613	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
614	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transplant Immunology, 2022, 70, 101495.	0.6	58
615	Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 24-28.	0.3	1
616	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infectious Diseases, The, 2022, 22, 473-482.	4.6	76
617	Case Report: Isolated, unilateral oculomotor palsy with anti-GQ1b antibody following COVID-19 vaccination. F1000Research, 2021, 10, 1142.	0.8	10
618	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22
619	SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines, 2021, 9, 1690.	1.4	7
620	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	1
621	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Reports, 2021, 37, 110114.	2.9	44

#	ARTICLE	IF	CITATIONS
623	Multibacillary leprosy unmasked by COVID-19 vaccination. <i>JAAD Case Reports</i> , 2022, 19, 87-89.	0.4	11
624	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. <i>Journal of Virology</i> , 2022, 96, JVI0197321.	1.5	35
625	BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity. <i>Vaccine</i> , 2021, 39, 7367-7374.	1.7	14
626	Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity. <i>Biomacromolecules</i> , 2021, , .	2.6	5
627	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
628	A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. <i>Kidney International</i> , 2022, 101, 390-402.	2.6	72
629	Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review. <i>Vaccines</i> , 2021, 9, 1404.	2.1	33
630	Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 752233.	2.2	68
631	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. <i>Current HIV/AIDS Reports</i> , 2022, 19, 5-16.	1.1	9
632	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
633	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. <i>Vaccines</i> , 2021, 9, 1338.	2.1	17
634	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
635	Nucleoside-Modified mRNA Vaccines Protect IFNAR <sup>1</sup> Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. <i>Journal of Virology</i> , 2022, 96, JVI0156821.	1.5	24
636	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
637	Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia. <i>Vaccines</i> , 2021, 9, 1297.	2.1	33
638	Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 732693.	2.2	5
639	Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics. <i>Journal of the American Chemical Society</i> , 2021, 143, 20529-20545.	6.6	16
640	Delayed hypersensitivity to the Comirnaty coronavirus disease 2019 vaccine presenting with pneumonitis and rash. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 321-322.	0.5	3

#	ARTICLE	IF	CITATIONS
641	Liposome Sterile Filtration Characterization via X-ray Computed Tomography and Confocal Microscopy. <i>Membranes</i> , 2021, 11, 905.	1.4	1
642	Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel. <i>Clinical Microbiology and Infection</i> , 2022, 28, 450.e1-450.e4.	2.8	8
643	Advances in mRNA and other vaccines against MERS-CoV. <i>Translational Research</i> , 2022, 242, 20-37.	2.2	11
644	Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 9-26.	1.0	17
645	Previous COVID-19 Infection and Antibody Levels After Vaccination. <i>Frontiers in Public Health</i> , 2021, 9, 778243.	1.3	69
646	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
647	Hookworm infection: Toward development of safe and effective peptide vaccines. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1394-1419.e6.	1.5	2
648	Miller Fisher Syndrome Presenting After a Second Dose of Pfizer-BioNTech Vaccination in a Patient With Resolved COVID-19: A Case Report. <i>Journal of Clinical Neuromuscular Disease</i> , 2021, 23, 113-115.	0.3	15
649	The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. <i>IScience</i> , 2021, 24, 103479.	1.9	224
650	Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on <sup>18</sup> F-FDG PET/CT: A Focus in Breast Cancer Care. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1231-1238.	2.8	10
651	Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 801-812.	2.6	40
652	Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy. <i>Immunity, Inflammation and Disease</i> , 2021, , .	1.3	10
654	Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. <i>Haematologica</i> , 2022, 107, 755-758.	1.7	6
655	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Host and Microbe</i> , 2022, 30, 97-109.e5.	5.1	83
656	Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110601.	0.7	15
657	Approved and marketed nanoparticles for disease targeting and applications in COVID-19. <i>Nanotechnology Reviews</i> , 2021, 10, 1941-1977.	2.6	43
658	Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110582.	0.6	18
659	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22



#	ARTICLE	IF	CITATIONS
661	Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 854-869.	2.3	21
662	Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103455.	0.9	13
663	Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers. <i>Nano Today</i> , 2022, 43, 101375.	6.2	9
664	Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals. <i>Clinical Immunology Communications</i> , 2022, 2, 6-11.	0.5	6
665	Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 757151.	2.2	3
666	Past and Current Progress in the Development of Antiviral/Antimicrobial Polymer Coating towards COVID-19 Prevention: A Review. <i>Polymers</i> , 2021, 13, 4234.	2.0	13
667	A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 824728.	2.2	14
668	An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution. <i>Biomedicines</i> , 2022, 10, 296.	1.4	25
669	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	2.2	19
670	Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	28
671	CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	16
672	Targeting memory T cell metabolism to improve immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	61
673	On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain. <i>Stochastic Environmental Research and Risk Assessment</i> , 2022, 36, 2941-2948.	1.9	5
674	Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 75.	2.1	8
675	Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2022, 10, e0118121.	1.2	15
677	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	6
678	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
679	TNF-Producing CD4 <sup>+</sup> T Cells Dominate the SARS-CoV-2-Specific T Cell Response in COVID-19 Outpatients and Are Associated with Durable Antibodies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
680	An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses. <i>Virologica Sinica</i> , 2022, 37, 266-276.	1.2	10
681	Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. <i>Future Oncology</i> , 2022, 18, 1235-1244.	1.1	24
682	An Outline of Contributing Vaccine Technologies for SARS CoV2 Advancing in Clinical and Preclinical Phase-Trials. <i>Recent Patents on Biotechnology</i> , 2022, 16, 122-143.	0.4	6
683	Role of vitamin D deficiency and comorbidities in COVID-19. <i>World Journal of Virology</i> , 2022, 11, 85-89.	1.3	2
684	Nanoagent-based theranostic strategies against human coronaviruses. <i>Nano Research</i> , 2022, 15, 1-15.	5.8	4
685	Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines. <i>Vaccines</i> , 2022, 10, 99.	2.1	13
686	Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. <i>Frontiers in Immunology</i> , 2021, 12, 766278.	2.2	13
688	Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences. <i>Vaccines</i> , 2022, 10, 182.	2.1	9
689	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
690	Polymorphism of the <sc>HLA</sc> system and weak antibody response to <sc>BNT162b2 mRNA</sc> vaccine. <i>Hla</i> , 2022, 99, 183-191.	0.4	15
691	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
692	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. <i>Nature Communications</i> , 2022, 13, 153.	5.8	45
693	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 250-259.	3.0	3
694	A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response. <i>Pharmaceutics</i> , 2022, 14, 107.	2.0	3
695	Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 694.	1.0	10
696	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. <i>Emerging Microbes and Infections</i> , 2022, 11, 452-464.	3.0	8
697	Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 784145.	2.2	19
698	Revisiting Metchnikoff's work in light of the COVID-19 pandemic. <i>Innate Immunity</i> , 2022, 28, 57-66.	1.1	1



#	ARTICLE	IF	CITATIONS
699	T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. <i>Haematologica</i> , 2022, 107, 1000-1003.	1.7	14
700	COVID-19 infection and BNT162b2 vaccine triggering sarcoid-like lesions in the same patient. Response to: Sarcoid-like reaction in a patient recovering from COVID-19 pneumonia. <i>JAAD Case Reports</i> , 2022, 23, 162-163.	0.4	8
701	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
702	Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers. <i>Laboratoriums Medizin</i> , 2022, 46, 107-114.	0.1	6
704	MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. <i>Cellular and Molecular Immunology</i> , 2022, 19, 234-244.	4.8	8
705	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120
706	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. <i>Vaccine</i> , 2022, 40, 206-212.	1.7	20
707	Renal side effects of COVID-19 vaccines in patients with immunoglobulin A nephropathy. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 124-127.	0.9	6
708	Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 137-142.	0.6	29
709	Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 832889.	2.2	3
710	The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population. <i>Journal of Immunology</i> , 2022, 208, 819-826.	0.4	9
711	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 214.e1-214.e11.	0.6	32
712	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases. <i>Journal of Biological Chemistry</i> , 2022, 298, 101478.	1.6	12
713	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 799-811.	1.9	10
714	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
715	Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment. <i>Leukemia and Lymphoma</i> , 2022, 63, 1474-1478.	0.6	3
716	Recent COVID-19 vaccination has minimal effects on the physiological responses to graded exercise in physically active healthy people. <i>Journal of Applied Physiology</i> , 2022, 132, 275-282.	1.2	16
717	Genomic, immunological, and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China. <i>Journal of Medical Virology</i> , 2022, 94, 2237-2249.	2.5	13

#	ARTICLE	IF	CITATIONS
718	Accuracy and real life performance of a novel interferon- $\gamma$ release assay for the detection of SARS-CoV2 specific T cell response. <i>Journal of Clinical Virology</i> , 2022, 148, 105098.	1.6	24
719	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. <i>Frontiers in Medicine</i> , 2021, 8, 758118.	1.2	15
720	The impact of lymphoid memory cells in different ages of COVID-19 patients. <i>Gene Reports</i> , 2022, 26, 101503.	0.4	3
721	Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. <i>JAAD International</i> , 2022, 6, 107-108.	1.1	10
722	IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115638.	0.8	6
723	COVID-19 vaccine therapeutic trials review: published results and registered protocols. <i>Journal of Global Health Reports</i> , 0, 5, .	1.0	0
724	<sc>SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. <i>International Journal of Dermatology</i> , 2022, 61, 1187-1204.	0.5	38
725	COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study. <i>Vaccines</i> , 2022, 10, 253.	2.1	6
726	Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. <i>Rheumatology</i> , 2022, 61, SI180-SI188.	0.9	37
727	Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester. <i>Viruses</i> , 2022, 14, 307.	1.5	31
728	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals: EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
729	Salivary antibodies are detected with a commercial anti-SARS-CoV-2 assay only after two doses of vaccine using serum thresholds. <i>Clinical Biochemistry</i> , 2022, 104, 66-69.	0.8	5
730	Robust Recombinant Expression of Human Placental Ribonuclease Inhibitor in Insect Cells. <i>Biomolecules</i> , 2022, 12, 273.	1.8	1
731	Possible mechanisms of neuropathies associated with the COVID-19 vaccines. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 491-492.	1.0	0
732	Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice. <i>Npj Vaccines</i> , 2022, 7, 17.	2.9	19
733	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity. <i>Frontiers in Microbiology</i> , 2021, 12, 812729.	1.5	5
734	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	65
735	How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. <i>Blood</i> , 2022, 139, 2294-2305.	0.6	9

#	ARTICLE	IF	CITATIONS
736	New-onset lichen planus arising after COVID-19 vaccination. <i>Dermatologic Therapy</i> , 2022, 35, e15374.	0.8	27
737	Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?. <i>Vaccines</i> , 2022, 10, 248.	2.1	1
738	Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine. <i>Transplantation Direct</i> , 2022, 8, e1257.	0.8	10
739	Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. <i>Npj Vaccines</i> , 2021, 6, 153.	2.9	46
740	Antibody responses to COVID-19 vaccines in older adults. <i>Journal of Medical Virology</i> , 2022, 94, 1650-1654.	2.5	11
741	Thyroiditis After COVID-19 mRNA Vaccine: A Case Series. <i>AACE Clinical Case Reports</i> , 2022, 8, 116-118.	0.4	17
742	Nanoscale Mapping of Recombinant Viral Proteins: From Cells to Virus-Like Particles. <i>ACS Photonics</i> , 2022, 9, 101-109.	3.2	4
743	Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. <i>Nature Nanotechnology</i> , 2022, 17, 337-346.	15.6	74
744	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
745	Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e1037-e1045.	2.9	90
747	Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study. <i>Chemotherapy</i> , 2022, 67, 91-95.	0.8	14
748	Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. <i>JCI Insight</i> , 2021, 6, .	2.3	54
749	Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010211.	2.1	37
750	Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. <i>Vaccines</i> , 2022, 10, 64.	2.1	144
751	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. <i>Science Translational Medicine</i> , 2021, , eabi8961.	5.8	22
752	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
753	SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 171.	0.4	0
754	Clinical characteristics of COVID-19 and the efficacy of vaccination in patients with hematologic malignancies. <i>Srpski Medicinski Åesopis Lekarske Komore</i> , 2022, 3, 75-86.	0.1	1

#	ARTICLE	IF	CITATIONS
755	Variation in Antibody Titers Determined by Abbott and Roche Elecsys SARS-CoV-2 Assays in Vaccinated Healthcare Workers. SSRN Electronic Journal, 0, , .	0.4	0
756	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	2.2	19
757	The prognostic value of S100A calcium binding protein family members in predicting severe forms of COVID-19. <i>Inflammation Research</i> , 2022, 71, 369-376.	1.6	12
758	A Case of New-Onset Lichen Planus after COVID-19 Vaccination. <i>Dermatology and Therapy</i> , 2022, 12, 801-805.	1.4	23
759	Antibody response to COVID-19 vaccination in patients with lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 728-736.	0.7	13
760	mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. <i>Viruses</i> , 2022, 14, 401.	1.5	30
761	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. <i>Journal of Infection</i> , 2022, 84, 171-178.	1.7	25
762	SARS-CoV-2 Immunization Orchestrates the Amplification of IFN $\gamma$ -Producing T Cell and NK Cell Persistence. <i>Frontiers in Immunology</i> , 2022, 13, 798813.	2.2	9
763	Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	53
764	Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments. <i>Frontiers in Neurology</i> , 2022, 13, 843081.	1.1	1
765	Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. <i>Viruses</i> , 2022, 14, 449.	1.5	5
766	T cell responses to SARS-CoV-2 in humans and animals. <i>Journal of Microbiology</i> , 2022, 60, 276-289.	1.3	8
768	Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 804808.	2.2	7
769	A Case With New-Onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination. <i>Neurologist</i> , 2022, 27, 147-150.	0.4	20
770	Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers. <i>Pathogens</i> , 2022, 11, 286.	1.2	14
771	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	3.7	102
772	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 677-685.	1.2	7
773	Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. <i>Frontiers in Immunology</i> , 2022, 13, 832501.	2.2	23

#	ARTICLE	IF	CITATIONS
774	COVID-19 Vaccination and The Eye. <i>American Journal of Ophthalmology</i> , 2022, 240, 79-98.	1.7	32
776	Cellular Immunityâ€”The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. <i>Vaccines</i> , 2022, 10, 442.	2.1	21
777	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
778	Vaccine based on folded receptor binding domainâ€”PreS fusion protein with potential to induce sterilizing immunity to SARSâ€”CoVâ€”2 variants. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2431-2445.	2.7	16
779	The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness. <i>Hypertension Research</i> , 2022, 45, 846-855.	1.5	21
780	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 77.	0.9	5
781	Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA. <i>Future Virology</i> , 2022, 17, 191-196.	0.9	17
782	Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. <i>Cardiology Clinics</i> , 2022, 40, 301-308.	0.9	4
783	COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1269-1270.	1.8	11
784	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
785	Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 2840-2847.	1.8	10
786	Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. <i>Molecular Biology Reports</i> , 2022, 49, 4943-4957.	1.0	29
787	Erythrodermic psoriasis eruption associated with <sc>SARSâ€”CoV</sc> â€”2 vaccination. <i>Dermatologic Therapy</i> , 2022, 35, e15380.	0.8	6
788	A Case of Minimal Change Disease after SARS-CoV-2 Vaccination under the Age of 18. <i>Avicenna Journal of Medicine</i> , 2022, 12, 031-033.	0.3	6
789	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. <i>Frontiers in Immunology</i> , 2022, 13, 842912.	2.2	31
790	Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 651.	1.5	17
791	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. <i>Nature Immunology</i> , 2022, 23, 532-542.	7.0	178
792	Development of a retention prediction model in ion-pair reversed-phase HPLC for nucleoside triphosphates used as mRNA vaccine raw materials. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1193, 123168.	1.2	2

#	ARTICLE	IF	CITATIONS
793	Current Status and Future Perspectives on mRNA Drug Manufacturing. <i>Molecular Pharmaceutics</i> , 2022, 19, 1047-1058.	2.3	44
794	mRNA Lipoplexes with Cationic and Ionizable Î±-Amino-lipophosphonates: Membrane Fusion, Transfection, mRNA Translation and Conformation. <i>Pharmaceutics</i> , 2022, 14, 581.	2.0	3
795	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
796	Herpetic anterior uveitis following Pfizerâ€™BioNTech coronavirus disease 2019 vaccine: two case reports. <i>Journal of Medical Case Reports</i> , 2022, 16, 127.	0.4	8
797	Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals. <i>Vaccines</i> , 2022, 10, 439.	2.1	7
798	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. <i>Emerging Microbes and Infections</i> , 2022, 11, 1058-1071.	3.0	63
799	Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). <i>Cancers</i> , 2022, 14, 1544.	1.7	3
800	Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. <i>Frontiers in Immunology</i> , 2022, 13, 839922.	2.2	26
802	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
803	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. <i>Neurology and Therapy</i> , 2022, 11, 741-758.	1.4	18
804	IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity. <i>EBioMedicine</i> , 2022, 77, 103922.	2.7	7
805	Current Developments and Challenges of mRNA Vaccines. <i>Annual Review of Biomedical Engineering</i> , 2022, 24, 85-109.	5.7	39
806	Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. <i>Nature Immunology</i> , 2022, 23, 543-555.	7.0	185
807	SARS-CoV-2 mRNA Vaccination and Gravesâ€™ Disease: A Report of 12 Cases and Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2324-e2330.	1.8	33
808	Detection, prevention and treatment of COVIDâ€™19 and opportunities for nanobiotechnology. <i>View</i> , 2022, 3, .	2.7	8
809	Rituximabâ€™treated patients with lymphoma develop strong <scp>CD8</scp> Tâ€™cell responses following <scp>COVID</scp>â€™19 vaccination. <i>British Journal of Haematology</i> , 2022, 197, 697-708.	1.2	22
810	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. <i>Frontiers in Immunology</i> , 2022, 13, 827242.	2.2	5
811	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. <i>Cell Reports</i> , 2022, 38, 110514.	2.9	23



#	ARTICLE	IF	CITATIONS
812	Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients. <i>Cellular Immunology</i> , 2022, 373, 104501.	1.4	3
813	Vaccines Against COVID-19: A Review. <i>Vaccines</i> , 2022, 10, 414.	2.1	8
815	Nanotechnology and COVID-19: quo vadis?. <i>Journal of Nanoparticle Research</i> , 2022, 24, 62.	0.8	6
816	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
817	Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. <i>Scientific Reports</i> , 2022, 12, 3788.	1.6	22
818	COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case Series. <i>Brain Sciences</i> , 2022, 12, 407.	1.1	36
820	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. <i>Frontiers in Immunology</i> , 2022, 13, 867962.	2.2	5
821	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. <i>Inflammation Research</i> , 2022, 71, 377-396.	1.6	11
822	Pandemic-response adenoviral vector and RNA vaccine manufacturing. <i>Npj Vaccines</i> , 2022, 7, 29.	2.9	12
823	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 537-542.	0.6	6
824	Two flares of Stillé's disease after two doses of the ChAdOx1 vaccine. <i>Clinical Rheumatology</i> , 2022, 41, 1591-1596.	1.0	8
825	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, e0039622.	1.2	6
826	Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. <i>Clinical and Experimental Medicine</i> , 2023, 23, 371-379.	1.9	14
827	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
828	Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. <i>Clinical Infectious Diseases</i> , 2022, 75, e594-e602.	2.9	27
829	New Onset Biopsy-Proven Nephropathies after COVID Vaccination. <i>American Journal of Nephrology</i> , 2022, 53, 325-330.	1.4	32
830	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. <i>Journal of Headache and Pain</i> , 2022, 23, 41.	2.5	43
831	Association of severity and mortality of Covid-19 cases among acute kidney injury and sexual dimorphism. <i>Molecular Biology Reports</i> , 2022, 49, 6753-6762.	1.0	1

#	ARTICLE	IF	CITATIONS
832	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
833	Case Report: Isolated, unilateral oculomotor palsy with anti-GQ1b antibody following COVID-19 vaccination. <i>F1000Research</i> , 0, 10, 1142.	0.8	4
834	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
835	SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine. <i>Journal of Clinical Immunology</i> , 2022, 42, 914-922.	2.0	16
837	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	5.8	30
838	Evaluating Pharmacistsâ€™ Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia. <i>Clinical Pharmacology: Advances and Applications</i> , 2022, Volume 14, 27-35.	0.8	1
839	An mRNA vaccine to prevent genital herpes. <i>Translational Research</i> , 2022, 242, 56-65.	2.2	15
840	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
841	Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC). <i>Vaccines</i> , 2022, 10, 558.	2.1	2
842	Specific antibody response of 14 common variable immunodeficiency patients to three BNT162b2 mRNA COVID-19 vaccinations. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, , .	0.5	0
843	In the shadow of antibodies: how T cells defend against COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 757-759.	0.5	2
844	Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France. <i>Journal of Clinical Virology</i> , 2022, 149, 105134.	1.6	1
845	Nanomaterials and Bioactive Compounds against SARS-CoV-2. <i>Journal of Nanomaterials</i> , 2022, 2022, 1-13.	1.5	3
847	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. <i>JCI Insights</i> , 2022, 7, .	2.3	13
848	Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. <i>Journal of Immunological Methods</i> , 2022, 504, 113258.	0.6	2
849	Hidradenitis suppurativa flares following COVID-19 vaccination: A case series. <i>JAAD Case Reports</i> , 2022, 23, 42-45.	0.4	28
850	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
851	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166393.	1.8	4



#	ARTICLE	IF	CITATIONS
852	Acute idiopathic maculopathy after COVID-19 vaccination. American Journal of Ophthalmology Case Reports, 2022, 26, 101479.	0.4	6
853	Immune Response to SARS-CoV-2 Vaccine in 2 Men. International Archives of Allergy and Immunology, 2022, 183, 350-359.	0.9	2
854	Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination. Obstetrics and Gynecology, 2022, 139, 181-191.	1.2	44
855	Lichenoid drug eruption after coronavirus disease 2019 vaccination. Journal of Dermatology, 2022, 49, .	0.6	2
856	Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort Study. Vaccines, 2022, 10, 35.	2.1	4
857	mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. Vaccines, 2021, 9, 1503.	2.1	23
858	Acute Mild Pancreatitis Following COVID-19 mRNA Vaccine in an Adolescent. Children, 2022, 9, 29.	0.6	7
860	Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers. Journal of Clinical Medicine Research, 2021, 13, 549-555.	0.6	8
861	Development of pemphigus vulgaris following mRNA SARS-CoV-2 BNT162b2 vaccination in an 89-year-old patient. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	10
862	Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines, 2021, 9, 1478.	2.1	5
863	Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination. Scientific Reports, 2021, 11, 24448.	1.6	30
864	Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, 171.	0.4	1
865	Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 595-597.	0.5	11
866	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology, 2021, 12, 759688.	2.2	29
868	Immunization against severe acute respiratory syndrome Coronavirus 2: an overview. African Health Sciences, 2021, 21, 1574-83.	0.3	2
869	The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19. Musculoskeletal Care, 2022, 20, 431-441.	0.6	6
870	Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. Transplant Infectious Disease, 2022, 24, e13772.	0.7	21
873	Reactivation of minimal change disease and IgA nephropathy after COVID-19 vaccination. CKJ: Clinical Kidney Journal, 2022, 15, 569-570.	1.4	9

#	ARTICLE	IF	CITATIONS
875	COVID-19 Pandemic: Outbreak, Potential Vaccines And Medications. Russian Open Medical Journal, 2021, 10, .	0.1	0
876	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications, 2021, 12, 7105.	5.8	22
878	Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure. PLoS Computational Biology, 2021, 17, e1009664.	1.5	4
879	Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 2021, 8, 67.	1.9	26
880	Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines. CKJ: Clinical Kidney Journal, 2022, 15, 961-973.	1.4	11
882	Nanoscience versus Viruses: The SARS-CoV-2 Case. Advanced Functional Materials, 2022, 32, 2107826.	7.8	8
883	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
884	Immune Response to COVID-19. , 0, , .		1
887	Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. Journal of Cell Biology, 2022, 221, .	2.3	60
888	Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers. Journal of Korean Medical Science, 2022, 37, e135.	1.1	6
890	Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib. Frontiers in Medicine, 2022, 9, 826537.	1.2	5
891	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. Npj Digital Medicine, 2022, 5, 49.	5.7	24
892	Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Rheumatology International, 2022, 42, 959-966.	1.5	9
893	Eyelid erythema after coronavirus vaccination. Medicina Clínica (English Edition), 2022, , .	0.1	0
894	Vestibular Neuritis Following COVID-19 Vaccination: A Retrospective Study. Cureus, 2022, , .	0.2	2
895	Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	14
897	Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response. Vaccines, 2022, 10, 585.	2.1	14
898	Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines. Chemical Record, 2022, 22, e202200005.	2.9	26

#	ARTICLE	IF	CITATIONS
899	Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. <i>European Journal of Immunology</i> , 2022, 52, 1297-1307.	1.6	37
900	Chemo-Enzymatic Modification of the 5' Cap To Study mRNAs. <i>Accounts of Chemical Research</i> , 2022, 55, 1249-1261.	7.6	13
901	Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4493.	1.8	9
902	Protein engineering responses to the COVID-19 pandemic. <i>Current Opinion in Structural Biology</i> , 2022, 74, 102385.	2.6	11
903	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	15
904	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
906	Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. <i>HemaSphere</i> , 2022, 6, e688.	1.2	1
907	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. <i>Cell Journal</i> , 2021, 23, 523-531.	0.2	4
908	Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine.. <i>Medicina Del Lavoro</i> , 2021, 112, 477-485.	0.3	6
909	Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan. <i>Emerging Infectious Diseases</i> , 2022, 28, 1518-1520.	2.0	13
910	Ethical Issues involving the development of Covid-19 vaccines: Role of vaccine development, clinical trials and speed of peer review in dissuading public vaccine hesitancy. <i>Ethics in Biology, Engineering &amp; Medicine</i> , 2022, , .	0.1	0
911	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. <i>Arthritis and Rheumatology</i> , 2022, 74, e21-e36.	2.9	49
912	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. <i>MBio</i> , 2022, 13, e0018122.	1.8	20
913	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996.	1.4	3
914	Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. <i>Frontiers in Immunology</i> , 2022, 13, 869990.	2.2	40
915	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
916	Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. <i>Journal of Neurology</i> , 2022, 269, 4000-4012.	1.8	9
917	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3

#	ARTICLE	IF	CITATIONS
918	TNF- $\pm$ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100640.	3.3	15
919	Plasmablast-like Phenotype Among Antigen-Experienced CXCR5 <sup>+</sup> CD19 <sup>low</sup> B Cells in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1556-1568.	2.9	10
920	Three cases of thyroiditis after COVID-19 RNA-vaccine. <i>Annales D'Endocrinologie</i> , 2022, , .	0.6	6
921	Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. <i>Antibodies</i> , 2022, 11, 35.	1.2	3
922	Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	3
923	New-Onset Acute Kidney Disease Post COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 742.	2.1	12
924	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
925	Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. <i>Clinical Kidney Journal</i> , 2022, 15, 1574-1582.	1.4	7
927	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. <i>EBioMedicine</i> , 2022, 80, 104048.	2.7	12
928	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2. <i>Vaccine: X</i> , 2022, 11, 100165.	0.9	8
929	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. <i>Molecular Medicine</i> , 2022, 28, 54.	1.9	18
930	New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 909-916.	0.7	6
931	RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 43-53.	2.0	5
932	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. <i>EBioMedicine</i> , 2022, 80, 104062.	2.7	10
933	Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2071080.	1.4	12
936	Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. <i>Vaccines</i> , 2022, 10, 830.	2.1	5
937	Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
938	Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults. <i>Vaccines</i> , 2022, 10, 805.	2.1	5

#	ARTICLE	IF	CITATIONS
939	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1391-1414.	1.8	8
940	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	1.8	7
941	Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population. <i>Clinical Infectious Diseases</i> , 2023, 76, e391-e399.	2.9	12
942	What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions. <i>Vaccines</i> , 2022, 10, 866.	2.1	13
943	Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study. <i>Vaccines</i> , 2022, 10, 862.	2.1	5
944	Severe Relapsed Autoimmune Hemolytic Anemia after Booster with mRNA-1273 COVID-19 vaccine. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .	0.1	5
945	The Impact of the Epidemiological Situation Resulting From COVID-19 Pandemic on Selected Aspects of Mental Health Among Patients With Cancer in Silesia Province (Poland). <i>Frontiers in Psychology</i> , 2022, 13, .	1.1	2
947	Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. <i>Biomedicines</i> , 2022, 10, 1260.	1.4	6
948	A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 4091-4114.	1.7	6
949	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. <i>Russian Pediatric Journal</i> , 2022, 25, 139-146.	0.0	0
950	Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. <i>Vaccines</i> , 2022, 10, 871.	2.1	13
951	COVID-19 Vaccine: A Possible Trigger for Pyoderma Gangrenosum. <i>Cureus</i> , 2022, , .	0.2	3
952	Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	12
953	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
954	Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	7
955	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. <i>Med</i> , 2022, 3, 468-480.e5.	2.2	2
956	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
957	Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	12

#	ARTICLE	IF	CITATIONS
958	mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	34
959	One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach. <i>Canadian Geriatrics Journal</i> , 2022, 25, 212-221.	0.7	0
961	A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats. <i>Research in Veterinary Science</i> , 2022, 148, 52-64.	0.9	0
963	Advances in Circular RNA and Its Applications. <i>International Journal of Medical Sciences</i> , 2022, 19, 975-985.	1.1	46
964	Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 222.	1.1	10
966	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. <i>Molecular Immunology</i> , 2022, 149, 107-118.	1.0	2
967	Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population. <i>Vaccines</i> , 2022, 10, 985.	2.1	11
968	Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination. <i>Future Oncology</i> , 2022, 18, 2537-2550.	1.1	4
969	Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 956.	2.1	8
970	Artificial intelligence and clinical data suggest the T cell mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity. <i>Vaccine</i> , 2022, , .	1.7	4
971	Oral lesions after COVID-19 vaccination: Immune mechanisms and clinical approach. , 2022, 1, 171-179.		8
972	Combined assessment of Sâ€•and Nâ€•specific <sc>IL</sc>â€•2 and <sc>IL</sc>â€•13 secretion and <sc>CD69</sc> neoâ€•expression for discrimination of postâ€•infection and postâ€•vaccination cellular <sc>SARSâ€•CoV</sc>â€•2â€•specific immune response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3408-3425.	2.7	7
973	Reply to â€•Development of severe pemphigus vulgaris following <sc>SARSâ€•CoV</sc>â€•2 vaccination with <sc>BNT162b2</sc>â€•™ by Solimani <i>etâ€•al</i>.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	25
974	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
975	Perinatally Human Immunodeficiency Virusâ€•Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity. <i>Clinical Infectious Diseases</i> , 2022, 75, S51-S60.	2.9	7
976	High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. <i>Viruses</i> , 2022, 14, 1257.	1.5	7
977	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. <i>Archives of Virology</i> , 0, , .	0.9	1
978	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11



#	ARTICLE	IF	CITATIONS
979	Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. <i>Nature Cancer</i> , 2022, 3, 1039-1051.	5.7	12
980	Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. <i>Cell Reports</i> , 2022, 39, 111013.	2.9	16
981	How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response. <i>Diagnostics</i> , 2022, 12, 1401.	1.3	1
982	Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: "Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa". <i>Clinical and Experimental Dermatology</i> , 2022, 47, 2026-2028.	0.6	15
983	Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood. <i>ImmunoHorizons</i> , 2022, 6, 398-407.	0.8	0
984	Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose. <i>Hormones</i> , 0, , .	0.9	5
985	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
986	Ulcerative injection site reaction after third COVID-19 vaccine dose with mRNA vaccine. <i>Dermatologic Therapy</i> , 0, , .	0.8	1
987	Use of Nanomaterials for Diagnosis and Treatment: The Advancement of Next-Generation Antiviral Therapy. <i>Microbial Drug Resistance</i> , 2022, 28, 670-697.	0.9	4
988	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. <i>Journal of Autoimmunity</i> , 2022, 131, 102848.	3.0	10
989	Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual. , 2022, 1, 20220009.		1
990	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. <i>International Journal of Medical Sciences</i> , 2022, 19, 1122-1130.	1.1	0
991	Lichen planus after COVID-19 vaccination: A report of two cases. <i>Journal of Dermatology &amp; Dermatologic Surgery</i> , 2022, 26, 57.	0.1	1
993	Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes. <i>Journal of Virology</i> , 2022, 96, .	1.5	10
995	The potential of developing a protective peptide-based vaccines against SARS-CoV-2. <i>Drug Development Research</i> , 0, , .	1.4	2
996	Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects. <i>Pathogens</i> , 2022, 11, 743.	1.2	11
997	mRNA vaccines: Past, present, future. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 491-522.	4.3	24
998	A Diagnostic Strategy for Gauging Individual Humoral Ex Vivo Immune Responsiveness Following COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1044.	2.1	3



#	ARTICLE	IF	CITATIONS
999	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. <i>Advances in Therapy</i> , 2022, 39, 3789-3798.	1.3	3
1000	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1001	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1002	Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1122.	2.1	12
1003	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
1004	The Role of Vitamin D for Modulating the T Helper 1 Immune Response After the Coronavac Vaccination. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 329-335.	0.5	3
1005	Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies. <i>Journal of Clinical Medicine</i> , 2022, 11, 3968.	1.0	7
1006	Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. <i>Immunity</i> , 2022, 55, 1732-1746.e5.	6.6	40
1007	Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease. , 2022, 1, 634-648.		5
1008	Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. <i>Communications Medicine</i> , 2022, 2, .	1.9	9
1009	Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1010	Case of adult-onset Kawasaki disease and multisystem inflammatory syndrome following SARS-CoV-2 vaccination. <i>BMJ Case Reports</i> , 2022, 15, e249094.	0.2	3
1011	Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient. <i>Internal Medicine</i> , 2022, 61, 2215-2219.	0.3	4
1012	Delayed urticaria after the third dose of mRNA COVID19 vaccine: A case series. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	5
1013	Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. <i>Journal of Big Data</i> , 2022, 9, .	6.9	21
1014	Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1. <i>Biomedicines</i> , 2022, 10, 1622.	1.4	4
1015	The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses. <i>Cell Reports</i> , 2022, 40, 111138.	2.9	13
1016	Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection*. <i>Immunological Reviews</i> , 2022, 309, 75-85.	2.8	32

#	ARTICLE	IF	CITATIONS
1017	Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions. <i>Antibodies</i> , 2022, 11, 49.	1.2	8
1018	Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS-CoV-2 and variants. <i>MedComm</i> , 2022, 3, .	3.1	1
1019	Exacerbation of psoriasis following vaccination with the <sc>Pfizer&BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment. <i>Journal of Dermatology</i> , 2023, 50, .	0.6	4
1020	The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines. <i>International Journal of Translational Medicine</i> , 2022, 2, 309-331.	0.1	0
1021	Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud. <i>Horizonte M&amp;Ccedilico</i> , 2022, 22, e1937.	0.1	0
1022	Reactions in leprosy patients triggered by <sc>COVID-19 vaccination &quot; a cross-sectional study from a tertiary care centre in India. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	5
1024	Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1676.	1.4	5
1025	Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis. <i>Vaccines</i> , 2022, 10, 1135.	2.1	12
1026	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. <i>Nature Biomedical Engineering</i> , 2022, 6, 791-805.	11.6	100
1027	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1028	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
1029	Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV. <i>Aids</i> , 2022, 36, 1315-1317.	1.0	7
1030	Resolving adjuvant mode of action to enhance vaccine efficacy. <i>Current Opinion in Immunology</i> , 2022, 77, 102229.	2.4	14
1031	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. <i>iScience</i> , 2022, 25, 104719.	1.9	0
1032	Vacunas contra la COVID-19. <i>Ambiociencias</i> , 0, , 75-108.	0.0	1
1033	Lipid&Polymer Hybrid &Partic&in&Partic&Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID-19 Vaccines. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	16
1034	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. <i>ELife</i> , 0, 11, .	2.8	12
1035	mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	31

#	ARTICLE	IF	CITATIONS
1036	mRNA-based modalities for infectious disease management. <i>Nano Research</i> , 2023, 16, 672-691.	5.8	7
1037	Nanotechnologyâ€facilitated vaccine development during the coronavirus disease 2019 (COVIDâ€19) pandemic. <i>Exploration</i> , 2022, 2, .	5.4	22
1038	Immune responses to <scp>SARSâ€CoV</scp>â€2 vaccination in multiple sclerosis: a systematic review/metaâ€analysis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1321-1331.	1.7	16
1039	Short-Term Effect of SARS-CoV-2 Spike Protein Receptor-Binding Domain-Specific Antibody Induction on Neutrophil-Mediated Immune Response in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8234.	1.8	1
1041	Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer. <i>Clinical Infectious Diseases</i> , 2023, 76, e510-e513.	2.9	8
1042	Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. <i>Viruses</i> , 2022, 14, 1642.	1.5	4
1043	Anti-TNFÎ± Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. <i>Vaccines</i> , 2022, 10, 1186.	2.1	8
1044	Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1045	Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
1048	Efficient and Improved Solution-Phase Synthesis of Modified RNA Dinucleotides: Versatile Synthons in Cap 1 mRNA Therapeutics. <i>Organic Process Research and Development</i> , 2022, 26, 2771-2778.	1.3	4
1050	Pemphigus vulgaris following second dose of <scp>mRNA</scp> â€( <scp>Pfizerâ€BioNTech</scp> ) <scp>COVIDâ€19</scp> vaccine. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
1051	Serum peptidome profiles immune response of COVID-19 Vaccine administration. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1052	Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections. <i>MBio</i> , 2022, 13, .	1.8	7
1053	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1054	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	2.1	8
1055	Nanoparticles in clinical trials of COVID-19: An update. <i>International Journal of Surgery</i> , 2022, 104, 106818.	1.1	22
1056	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. <i>Trends in Molecular Medicine</i> , 2022, 28, 1082-1099.	3.5	11
1057	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	1.8	4

#	ARTICLE	IF	CITATIONS
1059	Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
1060	<scp>COVID</scp>â€19 vaccine humoral response in frequent platelet donors with plateletpheresisâ€associated lymphopenia. <i>Transfusion</i> , 2022, 62, 1779-1790.	0.8	4
1061	Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 4500.	1.0	5
1062	Too advanced for assessment? Advanced materials, nanomedicine and the environment. <i>Environmental Sciences Europe</i> , 2022, 34, .	2.6	2
1063	Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. <i>Vaccine</i> , 2022, 40, 5445-5451.	1.7	3
1064	Reconsidering the need for gain-of-function research on enhanced potential pandemic pathogens in the post-COVID-19 era. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
1065	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e061584.	0.8	4
1066	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1067	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1068	Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of <i>Mycobacterium tuberculosis</i> . <i>Molecular Diversity</i> , 2023, 27, 1613-1632.	2.1	4
1069	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
1070	Emerging trends of research on mRNA vaccines: A co-citation analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1071	Extracellular RNAs from immune cells under obesityâ€”a narrative review. <i>ExRNA</i> , 0, 4, 18-18.	1.0	1
1072	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. <i>Cell Reports</i> , 2022, 40, 111214.	2.9	24
1073	Disinfectants against SARS-CoV-2: A Review. <i>Viruses</i> , 2022, 14, 1721.	1.5	26
1075	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. <i>JCI Insight</i> , 2022, 7, .	2.3	10
1076	Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevEM. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104104.	0.9	0
1077	Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 3791.	1.7	4

#	ARTICLE	IF	CITATIONS
1078	Multimerization of Ebola GP1 mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1079	New-onset IgA nephropathy following COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 26-39.	0.2	20
1080	Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019. <i>Journal of Dermatology</i> , 0, , .	0.6	7
1081	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. <i>International Immunopharmacology</i> , 2022, 111, 109161.	1.7	9
1082	A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. <i>Journal of Controlled Release</i> , 2022, 350, 256-270.	4.8	23
1083	New-Onset Lichen Planus Induced by the Pfizer COVID-19 Vaccine. <i>Case Reports in Dermatological Medicine</i> , 2022, 2022, 1-4.	0.1	2
1084	Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA) Tj ETQq0 0 0 rgBT /Qverlock 10	1.5	6
1085	Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review. <i>Children</i> , 2022, 9, 1467.	0.6	3
1086	Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
1087	Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.. <i>Immunology Letters</i> , 2022, 250, 1-6.	1.1	3
1088	Nucleic acid therapy in pediatric cancer. <i>Pharmacological Research</i> , 2022, 184, 106441.	3.1	3
1089	Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine. <i>Open Life Sciences</i> , 2022, 17, 1282-1295.	0.6	0
1090	Lipid Nanoparticle-Mediated Delivery of Therapeutic and Prophylactic mRNA: Immune Activation by Ionizable Cationic Lipids. <i>RNA Technologies</i> , 2022, , 237-255.	0.2	1
1091	COVID-19, influenza, and other acute respiratory viral infections: etiology, immunopathogenesis, diagnosis, and treatment. Part 2. Other acute respiratory viral infections. <i>Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia</i> , 2022, 40, 3.	0.1	0
1092	Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	2
1093	Two cases of adult-onset de novo immunoglobulin A vasculitis with nephritis: Post-Covishield (ChAdOx1 nCoV-19; Oxford Astra Zeneca) vaccination. <i>Indian Journal of Rheumatology</i> , 2022, 17, 294.	0.2	2
1094	Minimal change disease and COVID-19 vaccination: Four cases and review of literature. <i>Clinical Nephrology Case Studies</i> , 2022, 10, 54-63.	0.3	7
1095	Are Seasonality of Meteorological Factors Influenced COVID-19 Era in Contrasting Geographic Settings? A Case of Subtropical Country. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1096	mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. <i>Biomaterials Science</i> , 2022, 10, 5566-5582.	2.6	11
1097	Messenger RNA for Prophylaxis. <i>RNA Technologies</i> , 2022, , 17-40.	0.2	0
1098	SARS-COV-2 and Other mRNA Vaccines. <i>RNA Technologies</i> , 2022, , 113-138.	0.2	0
1099	Cellular Immunology: Transcriptional Basis of B and T Cell Lineages and Memory Cells – T Cell Memory to Viral Infections. , 2022, , .		0
1101	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. <i>Health Evaluation and Promotion</i> , 2022, 49, 462-469.	0.0	0
1103	Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 942-954.	5.7	8
1104	SARS-CoV-2 and the pancreas: What do we know about acute pancreatitis in COVID-19 positive patients?. <i>World Journal of Gastroenterology</i> , 0, 28, 5240-5249.	1.4	7
1105	Editorial: Antimicrobial peptides and mRNA therapy: Clinical, Veterinary, and plant pathology perspectives with special attention to combatting MDR pathogens. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1106	Directing the Way – Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery. <i>Pharmaceutical Research</i> , 2023, 40, 47-76.	1.7	10
1107	Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2022, 3, 481-489.	2.6	14
1108	Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1550.	2.1	4
1109	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. <i>IScience</i> , 2022, 25, 105209.	1.9	2
1110	Erythema multiforme following vaccination for SARS-CoV-2: Report of a case and review of the literature – Secondary Publication. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.4	2
1111	Graves’ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	11
1112	Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. <i>Nature Immunology</i> , 2022, 23, 1445-1456.	7.0	27
1114	Alcian Blue Staining to Visualize Intracellular Hyaluronic Acid-Based Nanoparticles. <i>Methods in Molecular Biology</i> , 2023, , 313-320.	0.4	2
1115	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
1116	The effect of SARS-CoV-2 BNT162b2 vaccine on the symptoms of women with endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 121-127.	0.8	3



#	ARTICLE	IF	CITATIONS
1117	New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination. <i>Viruses</i> , 2022, 14, 2143.	1.5	7
1118	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1120	Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan. <i>Brain, Behavior, and Immunity</i> , 2022, , .	2.0	2
1121	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1122	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
1123	An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. <i>Vaccines</i> , 2022, 10, 1546.	2.1	1
1125	Increased <scp>CD8</scp> T cell immunity after <scp>COVID</scp>â€19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3
1126	COVID-19 and cellular senescence. <i>Nature Reviews Immunology</i> , 2023, 23, 251-263.	10.6	54
1127	Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	9
1128	Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1129	Nanovaccines to combat virusâ€related diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	3
1130	A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 309-323.	1.8	14
1131	Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic. <i>Frontiers in Allergy</i> , 0, 3, .	1.2	3
1132	mRNA vaccines: A novel weapon to control infectious diseases. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
1133	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELDâ„¢ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1134	<i>Medicine</i> , 2021, 110, 2099-2103.	0.0	0
1135	Ocular effects caused by viral infections and corresponding vaccines: An overview of varicella zoster virus, measles virus, influenza viruses, hepatitis B virus, and SARS-CoV-2. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
1136	Electroporation in Clinical Applicationsâ€”The Potential of Gene Electrotransfer and Electrochemotherapy. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10821.	1.3	5



#	ARTICLE	IF	CITATIONS
1137	Dose optimisation and scarce resource allocation: two sides of the same coin. <i>BMJ Open</i> , 2022, 12, e063436.	0.8	5
1138	Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1139	IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1972-1979.	1.6	4
1140	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. <i>Journal of Infectious Diseases</i> , 2023, 227, 353-363.	1.9	2
1141	Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling. <i>Vaccine</i> , 2022, 40, 7032-7041.	1.7	4
1142	Rheum-CoV-2 Vaccination Case Series. <i>Journal of Clinical Rheumatology</i> , 2023, 29, 105-108.	0.5	2
1143	COVID-19 vaccinations in pregnancy: Save mother and baby from COVID-19 pandemic. <i>International Journal of Gynecology and Obstetrics</i> , 2023, 160, 864-873.	1.0	4
1144	COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2023, 51, 130-141.	1.7	11
1145	Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 1670.	2.1	1
1146	Nanotechnology-Driven Delivery Systems in Inoculation Therapies. <i>Methods in Molecular Biology</i> , 2023, , 39-57.	0.4	0
1147	Renal Side Effects of COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1783.	2.1	10
1148	Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines. <i>ACS Nano</i> , 2022, 16, 18936-18950.	7.3	22
1149	Strategies for the production of dsRNA biocontrols as alternatives to chemical pesticides. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	12
1151	An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	38
1152	Multiple Evanescent White Dot Syndrome Following COVID-19 mRNA Vaccination. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1240-1244.	1.0	5
1153	Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. <i>Minerva Gastroenterology</i> , 0, , .	0.3	0
1154	Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. <i>Nature Aging</i> , 2022, 2, 896-905.	5.3	20
1155	Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. <i>Vaccines</i> , 2022, 10, 1649.	2.1	3

#	ARTICLE	IF	CITATIONS
1156	Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection. <i>General Thoracic and Cardiovascular Surgery</i> , 0, , .	0.4	2
1157	Evaluation of hematological abnormalities in subjects vaccinated with BNT162b2 in a longitudinal cohort of the CORE study. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 0, , .	0.2	0
1158	Phenotypic and functional changes of T cell subsets after CoronaVac vaccination. <i>Vaccine</i> , 2022, 40, 6963-6970.	1.7	4
1159	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1160	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
1161	Assessing anti-SARS-CoV-2 cellular immunity in 571 vaccines by using an IFN- $\gamma$ release assay. <i>European Journal of Immunology</i> , 2022, 52, 1961-1971.	1.6	8
1162	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.	2.1	7
1163	Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers. <i>Vaccines</i> , 2022, 10, 1809.	2.1	1
1164	Female genital mucosal lesions associated with COVID-19 vaccination: A brief review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	1.3	2
1165	GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration. <i>Biomedicines</i> , 2022, 10, 2777.	1.4	5
1166	Hospitalization among vaccines for SARS-CoV-2 breakthrough infection after dose sparing strategies in Libya: A cohort study. <i>PLoS ONE</i> , 2022, 17, e0276425.	1.1	0
1167	Highly pathogenic coronaviruses and the kidney. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113807.	2.5	1
1168	Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. <i>Journal of Controlled Release</i> , 2022, 352, 338-370.	4.8	25
1169	Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC). <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211353.	1.5	6
1170	mRNA vaccines for COVID-19. , 2023, , 611-624.		0
1171	Reports of New and Recurrent Keratitis following mRNA-based COVID-19 Vaccination. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1169-1174.	1.0	2
1172	Letter to the editor regarding article "Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Prpic-Massari L. New-onset lichen planus and lichen planus flare in elderly women after COVID-19 vaccination. <i>J Cosmet Dermatol</i> . 2022;10.1111/jocd.15185". <i>Journal of Cosmetic Dermatology</i> , 2023, 22, 39-41.	0.8	0
1173	Dual activation profile of monocytes is associated with protection in Mexican patients during SARS-CoV-2 disease. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 7905-7916.	1.7	1

#	ARTICLE	IF	CITATIONS
1175	Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic. <i>IScience</i> , 2022, 25, 105544.	1.9	7
1177	The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1650-1663.	2.4	2
1178	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. <i>Arthritis and Rheumatology</i> , 2023, 75, .	2.9	45
1179	Immunogenicity of mRNA encoding RBD SARS-CoV-2 in complex with a polycationic carrier. <i>Meditinskii Akademicheskii Zhurnal</i> , 2022, 2, 243-248.	0.2	0
1180	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 687-704.	0.7	0
1181	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1948.	2.1	3
1182	A flare of systemic sclerosis potentially triggered by anti-SARS-CoV-2 mRNA vaccination. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	1
1183	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5
1184	Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients. <i>Clinical Immunology Communications</i> , 2023, 3, 1-5.	0.5	1
1185	Development of the mRNA vaccines to prevent COVID-19. <i>Journal of Applied Biotechnology &amp; Bioengineering</i> , 2022, 9, 109-111.	0.0	0
1186	Heterologous vaccination of BNT162b2 in Ad26. COV2.S-vaccinated healthcare workers elicits long-term humoral immune response. <i>South African Medical Journal</i> , 2022, 112, 827-838.	0.2	0
1187	COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part 2. Other Acute Respiratory Viral Infections. <i>Molecular Genetics, Microbiology and Virology</i> , 2022, 37, 107-116.	0.0	0
1188	Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, .	3.3	12
1189	The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6855.	1.0	7
1190	Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. <i>Clinical Research in Cardiology</i> , 2023, 112, 431-440.	1.5	31
1192	Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. <i>Science Advances</i> , 2022, 8, .	4.7	9
1193	Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2-Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	3
1194	Long-Term Effectiveness of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine on B Cell Compartment: Efficient Recall of SARS-CoV-2-Specific Memory B Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15046.	1.8	2

#	ARTICLE	IF	CITATIONS
1195	Current state of, prospects for, and obstacles to mRNA vaccine development. <i>Drug Discovery Today</i> , 2023, 28, 103458.	3.2	5
1196	Erythema nodosum after COVID-19 vaccine: Report of two pediatric cases. <i>Pediatric Dermatology</i> , 2023, 40, 660-663.	0.5	2
1197	Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1198	N2 modified dinucleotide cap analogs as a potent tool for mRNA engineering. <i>Rna</i> , 2023, 29, 200-216.	1.6	7
1200	Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems. <i>Pathogens</i> , 2022, 11, 1444.	1.2	10
1201	Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14988.	1.8	8
1202	Study of Excipients in Delayed Skin Reactions to mRNA Vaccines: Positive Delayed Intradermal Reactions to Polyethylene Glycol Provide New Insights for COVID-19 Arm. <i>Vaccines</i> , 2022, 10, 2048.	2.1	1
1203	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
1204	Corneal Complications after COVID-19 Vaccination: A Systemic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6828.	1.0	5
1205	COVID-19 Vaccination Is Associated with a Better Outcome in Acute Ischemic Stroke Patients: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6878.	1.0	3
1207	Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1208	Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine. <i>Virology Journal</i> , 2022, 19, .	1.4	5
1209	Characterization of Generalized Pustular Psoriasis in Northwest China: A Single-Center Retrospective Study. <i>International Journal of Dermatology and Venereology</i> , 2022, 5, 191-198.	0.1	1
1210	A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales. <i>Vaccine</i> , 2023, 41, 511-518.	1.7	3
1211	A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. <i>Science Advances</i> , 2022, 8, .	4.7	12
1213	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	10
1214	Engineered Lipid Nanoparticles for the Treatment of Pulmonary Fibrosis by Regulating Epithelialâ€¦Mesenchymal Transition in the Lungs. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	10
1215	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. <i>Pathogens and Immunity</i> , 2022, 7, 93-119.	1.4	0

#	ARTICLE	IF	CITATIONS
1216	A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1217	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CoV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. <i>Vaccines</i> , 2022, 10, 2110.	2.1	2
1218	Steroid treatment suppresses the CD4+ T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1220	Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	14
1221	A Thermal and Enzymatic Dual-Stimuli Responsive DNA-Based Nanomachine for Controlled mRNA Delivery. <i>Advanced Science</i> , 2023, 10, .	5.6	8
1222	IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report. <i>BMC Nephrology</i> , 2022, 23, .	0.8	3
1223	Nucleic Acid-based Vaccines. <i>Essentials</i> , 2023, , 29-34.	0.1	0
1224	Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	4
1225	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
1226	A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. <i>Npj Vaccines</i> , 2022, 7, .	2.9	20
1227	The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	4
1228	5-Ethynyluridine: A Bio-Orthogonal Uridine Variant for mRNA-Based Therapies and Vaccines. <i>ChemBioChem</i> , 2023, 24, .	1.3	0
1229	Targeting Ligand Independent Tropism of siRNA-LNP by Small Molecules for Directed Therapy of Liver or Myeloid Immune Cells. <i>Advanced Healthcare Materials</i> , 0, , .	3.9	7
1230	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 16, 145-160.	1.6	5
1231	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1232	Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge. <i>Neurological Sciences</i> , 2023, 44, 1141-1146.	0.9	3
1233	COVID vaccines inciting lepra reaction: An observation in a referral centre. , 0, 3, 11.		0
1234	Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. <i>Nature Aging</i> , 2023, 3, 82-92.	5.3	23

#	ARTICLE	IF	CITATIONS
1235	Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 908.	1.8	6
1236	A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1237	Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 11, 177-186.	0.3	1
1238	Research progress on circular RNA vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1239	New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 181-195.	0.2	2
1240	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
1241	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
1242	COVID-19 Vaccinesâ€™ All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
1243	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
1244	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
1245	The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review. <i>Vaccines</i> , 2023, 11, 69.	2.1	7
1246	Evolution Of SARS-CoV-2 In The Presence Of Vaccines. , 2022, , .		0
1247	An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. <i>Virologica Sinica</i> , 2023, 38, 244-256.	1.2	3
1248	Herpes Zoster Following COVID-19 Vaccine Booster. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	1
1249	Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease. <i>Infectious Disease Reports</i> , 2023, 15, 24-33.	1.5	0
1250	Corneal Allograft Endothelial Rejection after Sinopharm COVID-19 Vaccination; Report of Six Cases. <i>Seminars in Ophthalmology</i> , 2023, 38, 565-571.	0.8	2
1252	Vulvar Aphthous Ulcers in Perimenarchal Adolescents after COVID-19 Vaccination: A Multicenter Case Series. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2023, 36, 268-272.	0.3	5
1253	Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination. <i>Internal Medicine</i> , 2023, 62, 1043-1048.	0.3	1



#	ARTICLE	IF	CITATIONS
1254	Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1255	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
1256	Cutaneous adverse reaction following <scp>COVID</scp> â€19 vaccination: Report from a southern Italian referral centre. Comment on â€œcutaneous adverse reactions following the Pfizer/<scp>BioNTech COVID</scp> â€19 vaccineâ€•by Luo et al.. <i>Australasian Journal of Dermatology</i> , 0, , .	0.4	0
1257	T follicular helper 17 (Tfh17) cells are superior for immunological memory maintenance. <i>ELife</i> , 0, 12, .	2.8	11
1258	A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process. <i>Protein Expression and Purification</i> , 2023, 205, 106241.	0.6	0
1259	The DAMP-Driven Host Immune Defense Program Against Pathogens. , 2023, , 203-284.		0
1260	A Short Introduction to Vaccines. , 2023, , 1-32.		0
1261	Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis. <i>Allergologie Select</i> , 2023, 7, 84-89.	1.6	1
1262	A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. , 2023, 20, 351-364.		5
1263	Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 956-964.	4.6	6
1264	Brain gene therapy with Trojan horse lipid nanoparticles. <i>Trends in Molecular Medicine</i> , 2023, 29, 343-353.	3.5	13
1265	Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114457.	2.5	3
1266	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1267	Immunomodulatory nanosystems: An emerging strategy to combat viral infections. <i>Biomaterials and Biosystems</i> , 2023, 9, 100073.	1.0	3
1268	Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, , .	0.5	0
1269	Pemphigus aggravation following Pfizerâ€™BioNTech vaccination: A case report and review of literature. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 1187-1190.	0.9	1
1270	Assessment of Reactivity to the Administration of the mRNA Vaccine after Six Months of Observation. <i>Vaccines</i> , 2023, 11, 366.	2.1	1
1272	Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model. <i>Journal of Genetic Engineering and Biotechnology</i> , 2023, 21, 16.	1.5	0



#	ARTICLE	IF	CITATIONS
1273	Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines. <i>Life</i> , 2023, 13, 474.	1.1	1
1274	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1275	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. <i>PLoS ONE</i> , 2023, 18, e0281689.	1.1	8
1276	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	1.2	0
1277	Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	3
1278	Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	1.3	5
1279	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
1280	Pre-existing immunity modulates responses to mRNA boosters. <i>Cell Reports</i> , 2023, 42, 112167.	2.9	12
1281	Review on COVID-19 Vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5868-5874.	0.2	0
1282	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	4
1283	Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar. <i>Vaccines</i> , 2023, 11, 496.	2.1	2
1284	Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. <i>Vaccines</i> , 2023, 11, 524.	2.1	3
1286	Comparison of Humoral Response in Kidney Transplant Recipients and Donors and Healthy Volunteers Following Second Dose of SARS-CoV-2 mRNA Vaccine. <i>Transplantation Proceedings</i> , 2023, 55, 514-520.	0.3	0
1287	Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. <i>Heart Failure Clinics</i> , 2023, 19, 177-184.	1.0	0
1289	A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA. <i>PLoS ONE</i> , 2023, 18, e0281907.	1.1	2
1290	Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality. <i>Npj Vaccines</i> , 2023, 8, .	2.9	3
1291	Encephalitis following COVID-19 Vaccination: A Systematic Review. <i>Vaccines</i> , 2023, 11, 576.	2.1	7
1292	Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study. <i>Scientific Reports</i> , 2023, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
1293	<sc>Pfizer&#x2013;BioNTech</sc> vaccine induces the production of cross&#x2013;reactive antibodies against <i>Trypanosoma cruzi</i> proteins: A preliminary study. Tropical Medicine and International Health, 0, .	1.0	0
1294	NK cells in COVID-19&#x2013;from disease to vaccination. Journal of Leukocyte Biology, 2023, 114, 507-512.	1.5	2
1295	Pyrrole&#x2013;Imidazole Polyamides &#x2013; A Frontrunner in Nucleic Acid&#x2013;Based Small Molecule Drugs. Advanced Therapeutics, 2023, 6, .	1.6	1
1296	A novel mAb broadly neutralizes SARS&#x2013;CoV&#x2013;2 VOCs in vitro and in vivo, including the Omicron variants. Journal of Medical Virology, 2023, 95, .	2.5	1
1297	Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. Frontiers in Immunology, 0, 14, .	2.2	1
1298	Longer intervals between SARS&#x2013;CoV&#x2013;2 infection and mRNA&#x2013;1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
1299	Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine. Pharmaceutics, 2023, 15, 974.	2.0	10
1302	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. Blood Advances, 0, , .	2.5	1
1303	Durability of immune responses to mRNA booster vaccination against COVID-19. Journal of Clinical Investigation, 2023, 133, .	3.9	18
1304	A specific anti&#x2013;COVID&#x2013;19 BNT162b2 vaccine&#x2013;induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients. Clinical and Translational Immunology, 2023, 12, .	1.7	1
1305	Korean Red Ginseng Potentially Improves Maintaining Antibodies after COVID-19 Vaccination: A 24-Week Longitudinal Study. Nutrients, 2023, 15, 1584.	1.7	2
1306	Systemic Sarcoidosis with Cutaneous Tattoo Involvement Following COVID-19 Vaccination. Acta Dermato-Venereologica, 0, 103, adv6244.	0.6	5
1307	Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors. Cancers, 2023, 15, 2000.	1.7	2
1308	Concurrent Herpes Zoster and Psoriasis After mRNA COVID-19 Vaccine (BNT162b2): A Case Report. Journal of the Turkish Academy of Dermatology, 2023, 17, 35-36.	0.1	0
1309	Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications. Life, 2023, 13, 903.	1.1	6
1310	New Onset Glomerular Disease Post&#x2013;COVID-19 Vaccination: Is There a Link?. Kidney360, 2023, 4, 294-296.	0.9	2
1311	Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients. Frontiers in Immunology, 0, 14, .	2.2	2
1312	Assessing the generation of tissue resident memory T cells by vaccines. Nature Reviews Immunology, 2023, 23, 655-665.	10.6	10

#	ARTICLE	IF	CITATIONS
1313	Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2023, 16, 483-495.	0.7	1
1314	Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2023, 9, 205521732311651.	0.5	1
1316	SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. <i>Vaccines</i> , 2023, 11, 808.	2.1	1
1317	Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	2
1318	Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient. <i>Nature Communications</i> , 2023, 14, .	5.8	5
1319	Comparative analysis between STANDARDâ€ Coviâ€FERON ELISA with preâ€existing IFNâ€ <sup>Î³</sup> release assays and determination of the optimum cutoff value for assessment of Tâ€Cell response to SARSâ€CoVâ€2. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	1
1320	Seasonality of meteorological factors influencing the COVID-19 era in coastal and inland regions of Bangladesh. <i>Geocarto International</i> , 2023, 38, .	1.7	1
1321	The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. <i>Cell</i> , 2023, 186, 2392-2409.e21.	13.5	24
1322	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12
1323	Insights into new-onset autoimmune diseases after COVID-19 vaccination. <i>Autoimmunity Reviews</i> , 2023, 22, 103340.	2.5	18
1324	Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech). <i>Internal Medicine</i> , 2023, 62, 2013-2017.	0.3	2
1325	Immune Response and Transplacental Antibody Transfer in Pregnant Women after COVID-19 Vaccination. <i>Journal of Personalized Medicine</i> , 2023, 13, 689.	1.1	1
1329	mRNA Vaccine Platform: mRNA Production and Delivery. <i>Russian Journal of Bioorganic Chemistry</i> , 2023, 49, 220-235.	0.3	1
1336	Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review. <i>CEN Case Reports</i> , 2024, 13, 53-58.	0.5	0
1347	Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 2824-2842.	1.1	4
1363	Learning from cancer to address COVID-19. <i>Biologia Futura</i> , 2023, 74, 29-43.	0.6	0
1367	Knifeâ€™s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1305-1313.	3.2	11
1375	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0

#	ARTICLE	IF	CITATIONS
1403	N2 modified cap analogues as translation inhibitors and substrates for preparation of therapeutic mRNA. <i>European Biophysics Journal</i> , 0, , .	1.2	1
1416	Harnessing Knowledge from COVID-19 Scenario for New Generation Vaccine Development to Control Pandemics in Animals. <i>Livestock Diseases and Management</i> , 2023, , 249-279.	0.5	0
1457	Management of Immunosuppressed Dermatology Patients During COVID-19. <i>Updates in Clinical Dermatology</i> , 2023, , 109-120.	0.1	0
1458	Cutaneous Reactions to COVID-19 mRNA Vaccines. <i>Updates in Clinical Dermatology</i> , 2023, , 17-30.	0.1	0
1482	Therapeutic synthetic and natural materials for immunoengineering. <i>Chemical Society Reviews</i> , 2024, 53, 1789-1822.	18.7	0